WO2009113845A1 - High protein liquid enteral nutritional composition - Google Patents
High protein liquid enteral nutritional composition Download PDFInfo
- Publication number
- WO2009113845A1 WO2009113845A1 PCT/NL2008/050141 NL2008050141W WO2009113845A1 WO 2009113845 A1 WO2009113845 A1 WO 2009113845A1 NL 2008050141 W NL2008050141 W NL 2008050141W WO 2009113845 A1 WO2009113845 A1 WO 2009113845A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- nutritional composition
- protein
- liquid enteral
- enteral nutritional
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 208
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 88
- 239000007788 liquid Substances 0.000 title claims abstract description 81
- 102000004169 proteins and genes Human genes 0.000 title claims description 46
- 108090000623 proteins and genes Proteins 0.000 title claims description 46
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 101
- 235000021119 whey protein Nutrition 0.000 claims abstract description 78
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 73
- 102000034238 globular proteins Human genes 0.000 claims abstract description 60
- 108091005896 globular proteins Proteins 0.000 claims abstract description 60
- 230000035764 nutrition Effects 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims description 51
- 235000018102 proteins Nutrition 0.000 claims description 45
- 150000001720 carbohydrates Chemical class 0.000 claims description 44
- 239000005862 Whey Substances 0.000 claims description 23
- 238000010438 heat treatment Methods 0.000 claims description 23
- 239000000443 aerosol Substances 0.000 claims description 20
- 102000004407 Lactalbumin Human genes 0.000 claims description 12
- 108090000942 Lactalbumin Proteins 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 11
- 102000008192 Lactoglobulins Human genes 0.000 claims description 10
- 108010060630 Lactoglobulins Proteins 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000005018 casein Substances 0.000 claims description 7
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 7
- 235000021240 caseins Nutrition 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 5
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- 102000007562 Serum Albumin Human genes 0.000 claims description 4
- 108010071390 Serum Albumin Proteins 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 108010084695 Pea Proteins Proteins 0.000 claims description 2
- 108010073771 Soybean Proteins Proteins 0.000 claims description 2
- 229940071162 caseinate Drugs 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- 235000019702 pea protein Nutrition 0.000 claims 1
- 229940001941 soy protein Drugs 0.000 claims 1
- 239000013589 supplement Substances 0.000 abstract description 7
- 239000000047 product Substances 0.000 description 85
- 235000014633 carbohydrates Nutrition 0.000 description 34
- 238000002156 mixing Methods 0.000 description 34
- 239000002245 particle Substances 0.000 description 26
- 229920002245 Dextrose equivalent Polymers 0.000 description 25
- 230000008569 process Effects 0.000 description 22
- 238000010411 cooking Methods 0.000 description 17
- 239000003925 fat Substances 0.000 description 17
- 235000019197 fats Nutrition 0.000 description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 238000004925 denaturation Methods 0.000 description 14
- 230000036425 denaturation Effects 0.000 description 14
- 238000009928 pasteurization Methods 0.000 description 13
- 229910052500 inorganic mineral Inorganic materials 0.000 description 12
- 239000011707 mineral Substances 0.000 description 12
- 235000010755 mineral Nutrition 0.000 description 12
- 239000000839 emulsion Substances 0.000 description 11
- 238000009826 distribution Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 229920001542 oligosaccharide Polymers 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 235000013325 dietary fiber Nutrition 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 7
- 150000002482 oligosaccharides Chemical class 0.000 description 7
- 235000019640 taste Nutrition 0.000 description 7
- 239000007787 solid Substances 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000000265 homogenisation Methods 0.000 description 5
- 239000012263 liquid product Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 101710137760 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000001370 static light scattering Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000001612 cachectic effect Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000021140 nondigestible carbohydrates Nutrition 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- LWTDZKXXJRRKDG-KXBFYZLASA-N (-)-phaseollin Chemical compound C1OC2=CC(O)=CC=C2[C@H]2[C@@H]1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-KXBFYZLASA-N 0.000 description 2
- PHIQHXFUZVPYII-LURJTMIESA-O (S)-carnitinium Chemical compound C[N+](C)(C)C[C@@H](O)CC(O)=O PHIQHXFUZVPYII-LURJTMIESA-O 0.000 description 2
- 101800000263 Acidic protein Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229920000926 Galactomannan Polymers 0.000 description 2
- 239000005905 Hydrolysed protein Substances 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 2
- 244000043158 Lens esculenta Species 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- -1 less than 6 weight% Chemical compound 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000006180 nutrition needs Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229940108461 rennet Drugs 0.000 description 2
- 108010058314 rennet Proteins 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- 235000019871 vegetable fat Nutrition 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 108700000434 Cannabis sativa edestin Proteins 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920000887 Chrysolaminarin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 240000006497 Dianthus caryophyllus Species 0.000 description 1
- 235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010049076 End stage AIDS Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LRGRDKFVKMAPSZ-UHFFFAOYSA-N Excelsin Natural products CCN1CC2(O)CCC3OC4C5C(CC6(O)C7CC2C3(C17)C4C6(O)C5OC)OC LRGRDKFVKMAPSZ-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 101710094902 Legumin Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710163504 Phaseolin Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 102000002027 Tuberin Human genes 0.000 description 1
- 108050009309 Tuberin Proteins 0.000 description 1
- 244000030973 Vanilla pompona Species 0.000 description 1
- 101710196023 Vicilin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000019647 acidic taste Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 235000019666 ageusia Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 235000020113 brazil nut Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- ORDAZKGHSNRHTD-UXHICEINSA-N deguelin Chemical compound O1C(C)(C)C=CC2=C1C=CC1=C2O[C@@H]2COC(C=C(C(=C3)OC)OC)=C3[C@@H]2C1=O ORDAZKGHSNRHTD-UXHICEINSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- NEKNNCABDXGBEN-UHFFFAOYSA-L disodium;4-(4-chloro-2-methylphenoxy)butanoate;4-(2,4-dichlorophenoxy)butanoate Chemical compound [Na+].[Na+].CC1=CC(Cl)=CC=C1OCCCC([O-])=O.[O-]C(=O)CCCOC1=CC=C(Cl)C=C1Cl NEKNNCABDXGBEN-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- OQQPVKBRTSQMEC-VCVHXTQBSA-N excelsin Chemical compound O[C@@H]([C@]1(C)[C@@H]23)[C@@H](O)C=C(C)[C@@H]1C[C@@H]1[C@@]43CO[C@@]2(O)[C@H](O)[C@H](C)[C@@H]4[C@@H](OC(=O)C(C)CC)C(=O)O1 OQQPVKBRTSQMEC-VCVHXTQBSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019211 fat replacer Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000008543 heat sensitivity Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 235000021332 kidney beans Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- LWTDZKXXJRRKDG-UHFFFAOYSA-N phaseollin Natural products C1OC2=CC(O)=CC=C2C2C1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- SZCZSKMCTGEJKI-UHFFFAOYSA-N tuberin Natural products COC1=CC=C(C=CNC=O)C=C1 SZCZSKMCTGEJKI-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- This invention is concerned with a method for the heat-treatment of a non-hydrolysed globular protein, the non-hydrolysed heat-treated globular protein per se, a shelf-stable liquid enteral nutritional composition with a high content of non-hydrolysed globular protein as a major protein source, processes for the preparation thereof and use of said liquid enteral nutritional composition for the treatment of persons in need thereof.
- These patients can be cachectic patients or persons suffering from end-stage AIDS, cancer or cancer treatment, severe pulmonary diseases like COPD (chronic obstructive pulmonary disease), tuberculosis and other infection diseases or persons that experienced severe surgery or trauma like burns.
- severe pulmonary diseases like COPD (chronic obstructive pulmonary disease), tuberculosis and other infection diseases or persons that experienced severe surgery or trauma like burns.
- COPD chronic obstructive pulmonary disease
- tuberculosis other infection diseases or persons that experienced severe surgery or trauma like burns.
- persons suffering from disorders in the throat or mouth such as oesophageal cancer or stomatitis and persons having problems with swallowing like dysphagic persons, require special liquid, low-volume nutrition.
- persons just suffering from reduced appetite or loss of taste will benefit from low- volume, preferably liquid, food.
- These patients can also be elderly persons, in particular frail elderly and elderly at risk of becoming frail.
- an elderly person's energy needs may be reduced, their ability to consume products may also be diminished.
- they may have difficulty consuming a product due to, e.g., swallowing difficulties, or due the too large amount of product they need to consume to meet the daily intake of nutrients.
- compliance is not optimal, and often, the intake is suboptimal, leading to suboptimal nourishment, and in the end, to malnutrition.
- an elderly person is a person of the age of 50 or more, in particular of the age of 55 or more, more in particular of the age of 60 or more, more in particular of the age of 65 or more.
- This rather broad definition takes into account the fact that the average age varies between different populations, on different continents, etc.
- Most developed world countries have accepted the chronological age of 65 years as a definition of 'elderly' or older person (associated with the age at which one may begin to receive pension benefits), but like many westernized concepts, this does not adapt well to e.g. the situation in Africa.
- UN United Nations
- the more traditional African definitions of an elder or 'elderly' person correlate with the chronological ages of 50 to 65 years, depending on the setting, the region and the country.
- the aforementioned groups of patients may be extremely sensitive to food consistency and to the organoleptic properties of the product such as, for instance viscosity, mouth feel, taste, smell and colour.
- patients such as cachectic patients, typically suffer from extreme weakness which often prevents them from sitting in a vertical position and from their ability to drink the food from a carton or even to suck it from a straw. These patients benefit well from liquid low-volume enteral compositions with a high content of nutrients.
- the problem underlying the present invention is to provide a shelf-stable liquid enteral composition for providing nutrition, either as a supplement, or as a complete nutrition, with a high content of non-hydro lysed globular protein as major protein source, in particular whey proteins, in the smallest volume of liquid, and which supports nutrition and well-being in the different patient groups mentioned above.
- enteral means any form of administration that involves any part of the gastrointestinal tract, i.e. by mouth (orally), by gastric feeding tube, duodenal feeding tube, or gastrostomy, and rectally.
- EP 0 486 425 A2 (Sandoz Nutrition, published 20 May 1992) discloses a liquid nutritional composition comprising 3.9 weight% of WPC having an energy density of 1.0 kcal/ml.
- EP 0 747 395 discloses a product for treating renal patients having an energy density of 1.6-2.25 kcal/ml and comprising free amino acids and whey proteins, wherein the ratio of essential amino acids to non-essential amino acids is 2- 4:1.
- free amino acids By using free amino acids, the amino acid composition is improved without increasing the viscosity.
- the taste is not acceptable for cachectic persons or other persons which have difficulties in eating the proper volume of food.
- the amount of protein is about 3 to 4 g/100 ml ofproduct.
- EP 1 314 361 discloses a nutritionally complete calorically dense formula comprising maximum 8 g/100 ml intact whey protein using WPI as a source of whey (Example 1).
- the whey solution is acidified to a pH of 3.0, UHT treated at
- WO 2007/110411 and WO 2007/110421 disclose heat-treated whey protein micelles, obtained by a process which comprises a pH adjustment and a heat-treatment between 70 0 C and 95 0 C.
- the present invention relates in general to a shelf-stable liquid enteral composition for providing nutrition, either as a supplement, or as a complete nutrition, with a high protein content of a non- hydro lysed globular protein, in particular a whey protein.
- the present invention provides a shelf-stable liquid enteral nutritional composition based mainly on non-hydrolysed globular proteins, designed to meet the nutritional needs of persons in need thereof, in particular elderly, persons recovering from certain disease states, and malnourished persons .
- the composition provides an increased amount of proteins per unit volume while providing a sufficiently low viscosity to allow the composition to be easily consumed orally or be administered by tube.
- the taste of the composition is not diminished in comparison with a less concentrated composition based on non-hydrolysed whey proteins.
- a liquid enteral nutritional composition comprising 9 to 20 g of non-hydrolysed globular protein per 100 ml of the composition.
- said globular protein is a whey protein.
- the present invention concerns a method of providing nutrition to a person in need thereof, in particular elderly, persons recovering from certain disease states, and malnourished persons, comprising the steps of administering to said person the nutritional composition according to the present invention.
- the present invention concerns a process for the heat-treatment of non- hydrolysed globular proteins, to obtain heat-treated non-hydrolysed globular proteins with unique properties.
- said heat-treated non-hydrolysed globular protein is a whey protein.
- the unique properties allow not only the manufacture of a nutritional composition comprising 9 to 20 g of heat-treated non-hydrolysed globular per 100 ml of the composition, but the unique heat-treated non-hydrolysed globular protein is suitable for use in any nutritional composition comprising these unique heat-treated globular proteins as a protein source in any concentration.
- the present invention concerns the unique heat-treated non-hydrolysed globular proteins per se, obtainable by the process according to the invention, and any product, formulation or composition comprising said heat-treated globular proteins, in particular whey proteins.
- the invention is generally concerned with globular proteins.
- Globular proteins may be single chains, two chains or more chains which interact in the usual ways or there may be portions of the chains with helical structures, pleated structures, or completely random structures.
- Globular proteins are relatively spherical in shape as the name implies. They are distributed in both plant and animal tissues. For instance, albumins can be found in blood (serum albumin), milk (lactalbumin), egg white (ovalbumin), lentils (legumelin), kidney beans (phaseolin), and wheat (leucosin).
- Globulins can be found in blood (serum globulins), muscle (myosin), potato (tuberin), Brazil nuts (excelsin), hemp (edestin), whey (lactoglobulins, immunoglobulins, and lactoferrins), pea and lentils (legumin, vicilin), and soy. Also, many enzymes and other vegetable proteins are globular proteins.
- the invention is concerned with pea, soy and whey proteins, more in particular with whey proteins.
- whey protein One of the most superior classes of food protein is whey protein. It is known for its excellent amino acid profile, high cystein content, rapid digestion, and interesting bioactive proteins (lactoglobulins, immunoglobulins, and lactoferrins). Nutritionally speaking, whey protein is known as a naturally complete protein because it contains all of the essential amino acids required in the daily diet. It is also one of the richest sources of branched chain amino acids (BCAAs, in particular leucine) which play an important role in muscle protein synthesis. Moreover, some of the individual components of whey protein have been shown to prevent viral and bacterial infection and modulate immunity in animals.
- BCAAs branched chain amino acids
- Whey protein is the preferred choice of proteins to treat persons suffering from sarcopenia, but is also suitable for healthy persons, such as sportsmen and active elderly.
- any commercially available whey protein source may be used, i.e. whey obtained by any process for the preparation of whey known in the art, as well as whey protein fractions prepared thereof, or the proteins that constitute the bulk of the whey proteins being ⁇ -lactoglobulin, ⁇ -lactalbumin and serum albumin, such as liquid whey, or whey in powder form, such as whey protein isolate (WPI) or whey protein concentrate (WPC).
- WPI whey protein isolate
- WPC whey protein concentrate
- Whey protein concentrate is rich in whey proteins, but also contains other components such as fat, lactose and glycomacroprotein (GMP), a caseine- related non-globular protein.
- GMP glycomacroprotein
- Whey protein concentrate is produced by membrane filtration.
- whey protein isolate consists primarily of whey proteins with minimal amounts of fat and lactose. Whey protein isolate usually requires a more rigorous separation process such as a combination of micro filtration and ultra- filtration or ion exchange chromatography. It is generally understood that a whey protein isolate refers to a mixture in which at least 90 weight % of the solids are whey proteins.
- a whey protein concentrate is understood as having a percentage of whey proteins between the initial amount in the by-product (about 12 weight%) and a whey protein isolate.
- sweet whey obtained as a by-product in the manufacturing of cheese
- acid whey obtained as a by-product in the manufacturing of acid casein
- native whey obtained by milk microfiltration or rennet whey, obtained as a by-product in the manufacturing of rennet casein
- whey proteins may originate from all kinds of mammalian animal species, such as, for instance cows, sheep, goats, horses, buffalo's, and camels.
- the whey protein is of bovine origin.
- the whey protein source is available as a powder, preferably the whey protein source is a WPC or WPI.
- Whey protein isolate consists mainly of a mixture of ⁇ -lactoglobulin (about 65 weight%), ⁇ - lactalbumin (about 25 weight%) and serum albumin (about 8 weight%). These proteins are globular proteins that are sensitive to aggregation in the denaturated state.
- the denaturation temperature of ⁇ -lactoglobulin is pH-dependent; at pH 6.7, irreversible denaturation occurs when the protein is heated at temperatures above 65°C.
- a free thiol group is exposed in the denaturated state. This free thiol group can initiate inter -protein disulfide interactions leading to a polymerization reaction resulting in aggregate formation.
- ⁇ -Lactalbumin also has a denaturation temperature of about 65°C . Since ⁇ -lactalbumin does not have a free thiol group (only four disulfide bridges), solutions of pure ⁇ -lactalbumin are not irreversibly denaturated under most processing conditions. However, in the presence of ⁇ - lactoglobulin, as is the case in e.g.
- ⁇ -lactalbumin is more sensitive to irreversible denaturation through the formation of ⁇ -lactalbumin/ ⁇ - lactoglobulin complexes in which also disulfide bridges in ⁇ -lactoglobuline and ⁇ -lactalbumin are involved via interchange reactions. Also the circumstance that ⁇ -lactalbumin contains cystein residues is considered to contribute to a certain sensitivity to irreversible denaturation.
- Denaturated ⁇ -lactoglobulin and ⁇ -lactalbumin are both sensitive to calcium; this is particularly the case in the pH range of about 5 to about 8 where the protein carries a neutral to net negative charge. At pH 4, the protein carries a net positive charge and is less sensitive to calcium-induced aggregation.
- the size, shape and density of the protein aggregates are influenced by a number of environmental and processing parameters including temperature, heating rate, pressure, shear, pH and ionic strength. Depending on the combination of these parameters, the aggregates may form a space-filling network (gel), fibrils or compact micro-particles.
- the aggregates may form a space-filling network (gel), fibrils or compact micro-particles.
- microparticulated whey can be formed under specific ionic strength and shear conditions. These particles have a compact structure, a high intrinsic viscosity and a low specific volume. Further, it is known that a relationship exists between aggregates size and heating temperature for microparticulated whey produced under shear conditions. Microparticulated whey protein has received a lot of interest lately for application as a fat replacer or viscosity enhancer for yoghurt.
- a composition that comprises mainly globular proteins as a protein source, in particular whey proteins is subjected to a specific heat -treatment that comprises the steps of converting the composition into an aerosol and quickly heating and cooling said aerosol to obtain a composition of unique heat-treated globular proteins, in particular whey proteins.
- a specific heat -treatment that comprises the steps of converting the composition into an aerosol and quickly heating and cooling said aerosol to obtain a composition of unique heat-treated globular proteins, in particular whey proteins.
- the whey exhibits extensive polymerization during heating up when process temperatures pass the temperature window just above the denaturation temperature of the whey protein.
- the product is too thick, lumpy, sandy and extensive fouling is observed in the heating apparatus.
- the non-hydrolysed globular proteins are subjected to a heat- treatment, comprising the consecutive steps of: a) adjusting the pH of an aqueous composition comprising non-hydrolysed globular proteins to a value of between about 2 and 8; b) converting the composition comprising non-hydrolysed globular proteins obtained in step a) into an aerosol; c) subjecting the aerosol obtained in step b) to a temperature of 100 to 190 0 C during a time of about 10 to 300 milliseconds ; d) flash-cooling the heat-treated aerosol obtained in step c) to a temperature below 85 °C to obtain an aqueous solution comprising heat-treated globular proteins.
- the aqueous composition comprising non-hydrolysed globular proteins may contain, next to non-hydrolysed globular proteins, in particular whey, any other nutritional ingredients, such as other proteins, amino acids, fat, carbohydrates, fibers, minerals, vitamins, and the like, and that these ingredients may be present when subjecting the aqueous composition to the method according to the invention, in particular step b).
- the pH of the aqueous composition of non-hydrolysed globular proteins in step a) is about 2 to 5. More preferably, the pH of the aqueous composition of non- hydrolysed globular proteins in step a) is about 4. In yet another embodiment, the pH of the aqueous composition of non-hydrolysed globular proteins in step a) is about 6 to 8. More preferably, the pH of the aqueous composition of non- hydrolysed globular proteins in step a) is about 7.
- said globular proteins are whey proteins.
- the aerosol obtained in step b) is subjected to a temperature of 110 to 180 0 C, during a time of about 20 to 200 milliseconds, more preferably 40 to 150 milliseconds, more preferably 80 to 120 milliseconds. In another embodiment, the aerosol obtained in step b) is subjected to a temperature of 110 0 C, during a time of about 20 to 200 milliseconds, more preferably 40 to 150 milliseconds, more preferably 80 to 120 milliseconds.
- the aerosol obtained in step b) is subjected to a temperature of 170 0 C, during a time of about 20 to 200 milliseconds, more preferably 40 to 150 milliseconds, more preferably 80 to 120 milliseconds.
- step a) the pH of an aqueous composition of non-hydrolysed whey proteins is adjusted to a value of about 4 (acid whey solution), and the aerosol obtained in step b) is subjected to a temperature of 110 0 C, during a time of about 20 to 200 milliseconds, more preferably 40 to 150 milliseconds, more preferably 80 to 120 milliseconds.
- step a) the pH of an aqueous composition of non-hydrolysed whey proteins is adjusted to a value of about 7 (neutral whey solution), and the aerosol obtained in step b) is subjected to a temperature of 170 0 C, during a time of about 20 to 200 milliseconds, more preferably 40 to 150 milliseconds, more preferably 80 to 120 milliseconds.
- step c) the conversion of the composition of non-hydrolysed globular proteins obtained in step a) into an aerosol is done using a spray nozzle, as described below in detail.
- step d) is performed by transporting the aerosol into a vacuum chamber (flash-cooling) to remove an amount of water by evaporation, equivalent to the amount of steam used and the product is cooled by indirect cooling to a temperature of less than about 85°C, preferably less than about 60 0 C.
- flash-cooling flash-cooling
- the cooling preferably takes place nearly instantaneously, i.e. in a time window preferably of milliseconds.
- the liquid product is atomized, pasteurized and dried in a spray tower, thus providing a solid powder with less than 4% of moisture.
- the product is obtained as a solid, not as a liquid, and at different conditions of temperature and residence time.
- the pH is not given, but it may be assumed that the pH was neutral.
- the apparatus was operated differently, the major difference being that a liquid composition is obtained and that the aerosol is subjected to heat for a much longer time.
- the apparatus to carry out the invention may be selected by the skilled person based on the steps described above.
- the apparatus to carry out the invention comprises a nozzle for atomizing the composition (step b), a chamber to heat the aerosol (step c), and a chamber to cool the heated aerosol (step d).
- the heating is done by mixing the aerosol with steam of a certain temperature (and at a certain steam pressure).
- the apparatus may comprise a nozzle and a mixing chamber.
- a mixing chamber generally comprises one or more inflow openings for steam flows and for product flows, in which a product flow may optionally be premixed with a part of the steam. It may be preferable to select the mixing chamber such that only one product flow is atomized with one steam flow, since this simplifies the cleaning of the mixing chamber after use.
- a schematic representation of a suitable nozzle for atomization according to the invention is shown in EP 1351587, Fig. 1, in which a nozzle with mixing chamber is shown. Said Fig.l is included herein by reference. It turns out that a nozzle with mixing chamber can be very effectively used for the heat treatment of a product.
- a suitable mixing chamber is generally characterized in that steam and atomized product to be treated are mixed, while the volume throughput of the steam will be much greater than that of the atomized product to be treated and the residence time of the atomized product is sufficiently to obtain the desired heat- treated globular protein.
- the volume ratio between the steam flow and the product flow may range between, for instance, about 20:1 and 150:1. It is important that the pressure in the mixing chamber is higher than in the space to which the atomized product is passed.
- the form and size of the inflow openings for the steam flow (1) and the flow of the product in liquid form (2) in the mixing chamber and their mutual position are selected such that intensive mixing takes place between product and steam. It is noted that the inflow openings can be placed such that the steam flow and the product flow enter the mixing chamber in substantially parallel direction. This may take place in both a horizontally, vertically and diagonally manner. However, it is also possible that the steam flow and the product flow enter the mixing chamber at different angles, for instance a vertical steam flow and a horizontal product flow.
- the inflow openings are further arranged such that the product is atomized in small droplets, which after a short residence time in the mixing chamber (4) leave the mixing chamber through an outflow opening (5), for instance to a cooling chamber (6).
- the inflow opening(s) for the steam flow preferably contain a steam distribution plate (3).
- the average residence time and particle size of the atomized droplets can be varied.
- To set a suitable residence time in the mixing chamber is a simple matter of optimization for the skilled person and depends at least on the temperature and pressure in the mixing chamber.
- the mixing is preferably realized by contacting the atomized product flow and the steam flow close to the inflow opening of the product in the mixing chamber and bringing the steam at high speed around the atomized product. In a preferred embodiment, such a mixing takes place by bringing the steam near the product concentrically around the inflow opening of atomized product in the mixing chamber.
- the product flow to steam flow ratio can be varied in a ratio of 1.6 to 10 kg product in liquid form per kg steam. Very good results are realized at a wet product flow to steam flow ratio of 2.4 to 8 kg product in liquid form per kg steam.
- any type of mixing chamber is suitable in which steam and product can be mixed and atomized.
- Very suitable for mixing and atomizing a product-steam mixture according to the invention is a nozzle such as "two-fluid" type nozzle, an example of which is described in EP 0438783, Fig. 1 .
- This nozzle contains a small chamber at the end of a product line in which steam and product are combined. To increase the capacity, more nozzles can be used in a parallel arrangement.
- the temperature of the supplied saturated or superheated steam in the method according to the invention is preferably in the range of 100 and 190 0 C, more preferably between 100 and 180 0 C, still more preferably between 100 and 170 0 C.
- the temperature in the mixing chamber will be maintained at the desired level through the steam, although it is also possible that the mixing chamber itself is heated by another heat source.
- the particle size (aggregate size) of the flash-cooled aerosol (obtained in step d) is less than about 30 ⁇ m, more preferably less than about 10 ⁇ m, still more preferably less than 5 ⁇ m, and most preferably less than 1 ⁇ m.
- the nutritional composition may start to taste sandy, which is not favoured.
- the method according to the invention may not provide sufficient pasteurization or sterilization. For instance, 100 milliseconds at 110 0 C does not provide sufficient microbial sterility for a neutral product. However, 100 milliseconds at 170 0 C would provide sufficient sterility.
- the product obtained from step d) is further pasteurized using conventional equipment such as a plate or tubular heat exchanger, scraped surface heat exchanger or a retort to give the final product.
- conventional equipment such as a plate or tubular heat exchanger, scraped surface heat exchanger or a retort.
- the invention therefore also relates to the above described method according to the invention, comprising steps a), b), c) and d), subsequently comprising a pasteurization step using a plate heat exchanger.
- the plate heat exchanger is preferably operated at 92 0 C for 30 seconds.
- a sterile product is obtained from step d) or from the above mentioned subsequent pasteurization step, which can be filled aseptically in aseptic containers in a further process step.
- this invention makes it possible to produce a liquid enteral nutritional composition with a high content of non-hydrolysed globular protein , in particular whey protein, with a long shelf life and with a low viscosity.
- non-hydrolysed proteins is equivalent to “intact” proteins, meaning that the proteins have not been subjected to an hydrolysis process.
- minor amounts of hydrolysed proteins may be present in the source of non-hydrolysed proteins, or may be added to the formulation, such as additional amino acids, such as, for example leucine, isoleucine, and the like.
- minor should be understood as an amount of about 20 weight% or less, for example of about 10 weight% or less.
- the term “about” should be interpreted as a deviation of plus or minus 10 % of the given value.
- a liquid enteral nutritional composition comprising 9 to 20 g of non-hydrolysed globular proteins per 100 ml of the composition.
- the globular proteins are whey proteins.
- the amount of non-hydrolysed globular proteins are 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 gram per 100 ml of the composition, or any value in between the aforementioned values.
- the pH of the liquid enteral nutritional composition is about 2 to about 8. In another embodiment, the pH is about 2, 3, 4, 5, 6, 7, or 8 or any value in between the aforementioned values.
- the composition is acidic (yoghurt-like or juice-like) with a pH of about 4.
- Acidification may be achieved by any method known to the skilled person, such as the addition of an acid (such as, for instance lactic acid, citric acid, phosphoric acid) or through fermentation.
- an acid such as, for instance lactic acid, citric acid, phosphoric acid
- the thus obtained composition has a pleasant mild acidic taste which can be flavoured perfectly with a fruity flavour.
- the composition has a neutral pH (i.e. a pH of about 7).
- the thus obtained composition has a pleasant taste which may optionally be flavoured with e.g. vanilla, chocolate, caramel, banana, strawberry.
- the protein provides 10 % to 50 %, preferably at least 15 %, more preferably at least 20 %, at least 25 %, at least 30 % of the total energy content of the composition.
- the % of total energy is also abbreviated as En%; En% is thus short for energy percentage and represents the relative amount that a constituent contributes to the total caloric value of the composition.
- En% is thus short for energy percentage and represents the relative amount that a constituent contributes to the total caloric value of the composition.
- the high levels of protein are beneficial for patients who may not be physically capable of receiving a large volume, for example, fluid restricted patients. Such patients can be given a reduced level of fluid while still receiving a required amount of nutritional support per day.
- the term "at least” also includes the starting point of the open range. For example, an amount of "at least 95 weight%” means any amount equal to 95 weight % or above.
- the composition has an energy density of at least 0.36 kcal/ml, preferably at least 1.0 kcal/ml, preferably at least 1.5 kcal/ml, preferably at least 2.0 kcal/ml, more preferably at least 2.4 kcal/ml.
- the composition has a high energy density, it also has a sufficiently low viscosity to allow it to be consumed by persons that may have difficulty swallowing products or those that are tube fed.
- the amount of whey proteins in the liquid nutritional composition according to the invention is at least 85 weight%, more preferably at least 90 weight %, more preferably at least 95 weight% of the total protein present in the liquid nutritional composition.
- the composition may comprise up to about 40 weight% of a non-globular protein, such as casein, caseinate, micellar casein isolate and the like, and any mixture thereof, preferably less than or equal to 20 weight%, more preferably less than or equal to 10 weight% of the total protein present in the liquid nutritional composition.
- the composition may comprise a free amino acid, or a mixture of free amino acids, up to 5 g/ 100ml, more preferably less than 2g/100 ml, more preferably less than 1 g/100 ml, most preferably less than 0.5 g/100 ml
- composition according to the invention is designed to either supplement a person's diet or to provide complete nutritional support.
- the composition according to the invention may further comprise at least fat and/or carbohydrate and/or a source of vitamins and minerals and/or a source of prebiotics.
- the composition according the invention is a nutritionally complete composition.
- the liquid nutritional composition according to the invention further comprises fat, said fat providing between 20 to 40 % of the total energy content of the composition. For a 1.6 kcal/ml composition, this amounts to 32 to 64 kcal per 100 ml. For a 2.4 kcal/ml composition, this amounts to 48 to 96 kcal per 100 ml.
- the fat may include medium chain triglycerides (MCT, mainly 8 to 10 carbon atoms long), long chain triglycerides (LCT) or any combination of the two types. MCTs are beneficial because they are easily absorbed and metabolized in a metabolically-stressed patient. Moreover, the use of MCTs will reduce the risk of nutrient malabsorption. LCT sources, such as canola oil, rapeseed oil, or corn oil are preferred because they can reduce immune suppression associated with certain types of fatty acids concentrated in the body.
- the fat comprises 30 to 60 weight% of animal or algal fat, 40 to 70 weight% of vegetable fat and optionally 0 to 20 weight% of MCTs based on total fat of the composition.
- the animal fat preferably comprises a low amount of milk fat, i.e. lower than 6 weight%, especially lower than 3 weight%.
- a mixture of corn oil, egg oil, and/or canola oil and specific amounts of marine oil are used.
- Egg oils, fish oils and algal oils are a preferred source of non-vegetable fats.
- compositions that are to be consumed orally in order to prevent formation of off-flavours and to decrease a fishy after-taste, it is recommended to select ingredients that are relatively low in docosahexanoic acid (DHA), i.e. less than 6 weight%, preferably less than 4 weight% of the fat.
- DHA docosahexanoic acid
- Marine oils containing DHA are preferably present in the composition according to the invention in an amount lower than 25 weight%, preferably lower than 15 weight% of the fat.
- inclusion of eicosapentanoic acid (EPA) is highly desirable for obtaining the maximum health effect.
- the amount of EPA ranges preferably between 4 weight% and 15 weight%, more preferably between 8 weight% and 13 weight% of the fat.
- the weight ratio EPA:DHA is advantageously at least 6:4, for example between 2:1 and 10:1.
- the liquid nutritional composition according to the invention may beneficially comprise an emulsifier.
- an emulsifier may be used, such as lecithin, and generally the emulsifier contributes to the energy content of the fat in said composition.
- the liquid nutritional composition according to the invention further comprises carbohydrate, said carbohydrate providing between 30 to 60 % of the total energy content of the composition.
- the carbohydrate provides at least 40 % of the total energy content of the composition according to the invention.
- the composition of the carbohydrate preferably is such that high viscosities, excessive sweetness, excessive browning (Maillard reactions) and excessive osmolarities are avoided. Acceptable viscosities and osmolarities may be achieved by adjusting the average chain length (average degree of polymerisation, DP) of the carbohydrates between 1.5 and 6, preferably between 1.8 and 4. In order to avoid excessive sweetness, the total level of sucrose and fructose is less than 52 % and preferably less than 40 % of the weight of the carbohydrate, especially of the digestible carbohydrate.
- Long-chain digestible carbohydrates such as starch, starch fractions and mild starch hydrolysates (DP > 6, DE ⁇ 20), may also be present, preferably in an amount of less than 25 weight%, especially less than 15 weight% of the carbohydrate, and less than 6 g/100 ml, preferably less than 4 g/100 ml of the total liquid enteral composition according to the invention.
- the carbohydrate includes maltodextrose with a high DE (dextrose equivalent). In one embodiment the carbohydrate includes maltodextrose with a DE of > 20, preferably > 30 or even > 40, such as a DE of about 47. In one embodiment of the present invention, the carbohydrate includes maltodextrose with a high DE in an amount of at least 35 weight%, preferably at least 50 weight%, preferably at least 65 weight%, preferably at least 90 weight% of the total weight of carbohydrate. In one embodiment of the present invention, the carbohydrate includes maltodextrose with a low DE of 2 to 20.
- the carbohydrate includes maltodextrose with a low DE of 2 to 10, preferably with a low DE of about 2. In one embodiment of the present invention, the carbohydrate includes maltodextrose with a low DE in an amount of less than 35 weight%, preferably less than 20 weight%, preferably less than 10 weight% of the carbohydrate. Maltodextrose with a low DE may also be referred to as maltodextrine.
- the carbohydrate includes maltodextrose with a high DE, preferably a DE of > 20, preferably > 30 or even > 40, most preferably a DE of about 47 in combination with maltodextrose with a low DE, preferably a low DE of 2 to 20, more preferably a low DE of 2 to 10, most preferably with a low DE of about 2.
- maltodextrose with a low DE such as of about 2 gives rise to a high viscosity.
- Maltodextrose with a high DE, such as of about 47 gives rise to a low viscosity, but is very sweet.
- the combination of both maltodextroses optimizes the balance between sweetness and viscosity.
- the carbohydrate includes at least 65 weight%, preferably at least 90 weight%, based on total weight of carbohydrate of maltodextrose with a DE > 40, preferably with a DE of about 47 and 0 to 10 weight% of maltodextrose with a DE 2 to 10, preferably with a DE of about 2.
- the carbohydrate includes trehalose. As was indicated, it is one of the main objects of the invention to provide a nutritional composition with a low viscosity. Sucrose is very well suited for such purpose, but gives rise to very sweet compositions, which are in general disliked by the consumer.
- Maltodextrose with a low DE such as of about 2
- Maltodextrose with a high DE such as of about 47
- Maltodextrose with a high DE such as of about 47
- Trehalose is a preferred choice of carbohydrate, as it gives rise to a low viscosity, no undesired Maillard reactions and it has a sweetness about half of that of sucrose.
- the carbohydrate includes trehalose in an amount of 20 % to 60 % of the weight of the carbohydrate, in an amount of 20 % to 45 %, more preferably in an amount of 25 % to 45 % of the weight of the carbohydrate.
- the composition according to the invention may contain a variety of vitamins and minerals. Overall, the composition according to the invention preferably includes at least 100 % of the United States Recommended Daily Allowance (USRDA) of vitamins and minerals in a one litre portion. In one embodiment of the present invention, the composition according to the invention provides all necessary vitamins and minerals.
- the composition according to the invention preferably provides 6 mg of zinc per 100 ml of the composition which is beneficial for tissue repair in a healing patient.
- the composition according to the invention (also) provides 25 mg of vitamin C per 100 ml of the composition to aid patients with more severe healing requirements.
- the composition according to the invention (also) provides 2.25 mg iron per 100 ml of the composition. Iron is beneficial in maintaining bodily fluids as well as circulatory system functions in an elderly patient.
- the amount of divalent ions ranges between 170 mg/100 ml and 300 mg/100 ml and preferably between 180 mg/100 ml and 280 mg/100 ml.
- the amount of calcium ranges between 155 mg/100 ml and 300 mg/100 ml and preferably between 190 mg/100 ml and 250 mg/100 ml.
- the phosphorus content can be above
- Carnitin may advantageously be present in an amount of 8 mg/100 ml to 1000 mg/100 ml, preferably 10 mg/100 ml to 100 mg/100 ml of composition; it may have the form of carnitin, alkyl carnitin, acyl carnation or mixtures thereof.
- Organic acids are preferably present at a level of between 0.1 g/100 ml to 6 g/100 ml, especially 0.25 g/100 ml to 3 g/100 ml.
- these acids include short fatty acids such as acetic acid, hydroxy acids such as lactic acid, gluconic acid, and preferably polyvalent hydroxy acids, such as malic acid and citric acid.
- the present composition also comprises citric acid.
- the liquid enteral nutritional composition according to the invention may be fortified with a prebiotic, for example, with non-digestible carbohydrates (dietary fibres), such as fructo- oligosaccharides and/or inulin.
- dietary fibres such as fructo- oligosaccharides and/or inulin.
- the composition according to the invention comprises 0.5 g/100 ml to 6 g/100 ml of non-digestible carbohydrates.
- non-digestible carbohydrates are also referred to as dietary fibres.
- the dietary fibres include non-digestible oligosaccharides having a DP of 2 to 20, preferably 2 to 10. More preferably, these oligosaccharides do not contain substantial amounts (less than 5 weight%) of saccharides outside these DP ranges, and they are soluble.
- oligosaccharides may comprise fructo- oligosaccharides (FOS), trans-galacto-oligosaccharides (TOS), xylo-oligosaccharides (XOS), soy oligosaccharides, and the like.
- FOS fructo- oligosaccharides
- TOS trans-galacto-oligosaccharides
- XOS xylo-oligosaccharides
- soy oligosaccharides and the like.
- higher molecular weight compounds such as inulin, cellulose, resistant starch and the like may be incorporated in the composition according to the invention.
- the amount of insoluble dietary fibre such as cellulose is preferably lower than 20 weight% of the dietary fibre fraction of the composition according to the invention, and/or below 0.4 g/100 ml.
- the amount of thickening polysaccharides such as carrageenans, xanthans, pectins, galactomannans and other high molecular weight (DP > 50) indigestible polysaccharides is preferably low, i.e. less than 20 % of the weight of the dietary fibre fraction, or less than 1 g/100 ml.
- hydrolysed polysaccharides such as hydrolysed pectins and galactomannans can advantageously be included.
- a preferred dietary fibre component is an indigestible oligosaccharide with a chain length (DP) of 2 to 10, for example Fibersol® (resistant oligoglucose), in particular hydrogenated
- Fibersol® or a mixture of oligosaccharides having a DP of 2 to 10, such as fructo- oligosaccharides or galacto-oligosaccharides, which may also contain a small amount of higher saccharides (e.g. with a DP of 11 to 20).
- oligosaccharides preferably comprise 50 weight% to 90 weight% of the fibre fraction, or 0.5 g/100 ml to 3 g/100 ml of the composition according to the invention.
- Other suitable fibre components include saccharides that have only partial digestibility.
- the viscosity of the liquid enteral nutritional composition is lower than 500 mPa.s , measured at 20 0 C (i.e. room temperature) at a shear rate of 100 s "1 , preferably between 10 and 200 mPa.s , more preferably between 10 and 100 mPa.s, most preferably below 50 mPa.s.
- the viscosity may suitably be determined using a rotational viscosity meter using a cone/plate geometry. This viscosity is ideal for orally administering the liquid enteral nutritional composition according to the invention because a person may easily consume a serving having a low viscosity such as that displayed by the present invention. This viscosity is also ideal for unit dosages that are tube fed.
- the density of the composition ranges between 1.00 g/ml and 1.20 g/ml, especially between 1.10 g/ml and 1.18 g/ml.
- the liquid enteral nutritional composition according to the invention may have the form of a complete food, i.e. it can meet all nutritional needs of the user. As such, it preferably contains
- the daily dosage amounts are given with respect to a daily energy supply of 2000 kcal to a healthy adult having a body weight of 70 kg. For persons of different condition and different body weight, the levels should be adapted accordingly. It is understood that the average daily energy intake preferably is about 2000 kcal.
- the complete food can be in the form of multiple dosage units, e.g. from 4 (250 ml/unit) to 20 units (50 ml/unit) per day for an energy supply of 2000 kcal/day using a liquid enteral nutritional composition according to the invention of 2.0 kcal/ml.
- the liquid enteral nutritional composition can also be a food supplement, for example to be used in addition to a non-medical food.
- the liquid enteral nutritional composition contains per daily dosage less than 1500 kcal, in particular as a supplement, the liquid enteral nutritional composition contains 400 to 1000 kcal per daily dose.
- the food supplement can be in the form of multiple dosage units, e.g. from 2 (250 ml/unit) to 10 units (50 ml/unit) per day for an energy supply of 1000 kcal/day using a liquid enteral nutritional composition according to the invention.
- a unit dosage comprises any amount of the liquid enteral nutritional composition according to the invention between 10 ml and 250 ml, the end values of this range included, preferably any amount between 25 ml and 200 ml, the end values of this range included, more preferably any amount between 50 ml and 150 ml, the end values of this range included, most preferably about 125 ml.
- a person receiving 50 ml unit dosages can be given 10 unit dosages per day to provide nutritional support using a liquid enteral nutritional composition according to the invention of 2.0 kcal/ml.
- a person receiving 125 ml unit dosages can be given 4 or 5 or 6 or 7 or 8 unit dosages per day to provide nutritional support using a liquid enteral nutritional composition according to the invention.
- Such small dosage units are preferred because of better compliance.
- the composition is provided in a ready to use liquid form and does not require reconstitution or mixing prior to use.
- the composition according to the invention can be tube fed or administered orally.
- the composition according to the invention can be provided in a can, on spike, and hang bag.
- a composition may be provided to a person in need thereof in powder form, suitable for reconstitution using an aqueous solution or water such that the composition according to the invention is produced.
- the present composition is in the form of a powder, accompanied with instructions to dissolve or reconstitute in an aqueous composition or water to arrive at the liquid nutritional enteral composition according to the present invention.
- the present liquid nutritional enteral composition may thus be obtained by dissolving or reconstituting a powder, preferably in an aqueous composition, in particular water.
- the composition according to the invention is packaged.
- the packaging may have any suitable form, for example a block-shaped carton, e.g. to be emptied with a straw ; a carton or plastic beaker with removable cover ; a small- sized bottle for example for the 80 ml to 200 ml range, and small cups for example for the 10 ml to 30 ml range.
- Another suitable packaging mode is inclusion of small volumes of liquid (e.g. 10 ml to 20 ml) in edible solid or semi-solid hulls or capsules, for example gelatine-like coverings and the like.
- Another suitable packaging mode is a powder in a container, e.g. a sachet, preferably with instructions to dissolve or reconstitute in an aqueous composition or water.
- the liquid enteral nutritional composition according to the invention may be prepared by the method as outlined in Figure 1. Basically, the whey protein, carbohydrates and minerals are dispersed into water and the pH is adjusted using a suitable acid, such as lactic acid, citric acid, phosphoric acid and the like. The fat is blended into the product and this pre-emulsion is homogenized. This aqueous emulsion is subsequently atomized using the method of the invention, flash-cooled and collected. Optionally, the final pH and dry matter of the emulsion may be adjusted. The resulting product is subsequently pasteurized or sterilized using the known methods, such as, UHT processes and filled into containers or pasteurized or sterilized in containers in a retort.
- a suitable acid such as lactic acid, citric acid, phosphoric acid and the like.
- the fat is blended into the product and this pre-emulsion is homogenized.
- This aqueous emulsion is subsequently atomized using the method of the invention, flash-
- the liquid enteral nutritional composition according to the invention may alternatively be prepared by the method as outlined in Figure 7. Basically, the whey protein, carbohydrates and minerals are dispersed into water and the pH is adjusted using a suitable acid or base. The fat is blended into the product and this pre-emulsion is homogenized. This aqueous emulsion is subsequently atomized, flash-cooled and collected in an aseptic tank from which it can be filled into aseptic containers. Effectivity
- the present invention also concerns a method of providing nutrition to a person in need thereof, comprising the steps of administering to said person the nutritional composition according to the present invention.
- Said person may be an elderly person, a person that is in a disease state, a person that is recovering from a disease state, or a person that is malnourished.
- Said person may also be a healthy person, such as a sportsman or active elderly.
- the present invention relates to the non-hydrolysed heat-treated globular protein per se obtainable by the process according to the invention, and any product, formulation or composition comprising said heat-treated globular proteins, in particular whey proteins, in any form, such as a solution, suspension, dispersion, nutritional composition, medicament, or powder, in any concentration conceivable.
- Figure 1 Flow chart of a process for the manufacture of an acidic protein formula (12 g/100 ml) based on non-hydrolysed whey protein, according to the invention (Example 1 and Example 2).
- Figure 2 Particle size distribution of the formulation of Example 1, processed according to the flow chart of Figure 1, as measured with a Malvern Mastersizer 2000.
- Figure 3 Particle size distribution of the formulation of Example 1 , processed with a Scraped Surface Heat Exchanger (SSHE), as measured with a Malvern Mastersizer 2000.
- FIG. 4 Flow chart of a process for the manufacture of an acidic protein formula (16 g/100 ml) based on non-hydrolysed whey protein, according to the invention (Example 3).
- Figure 5 Particle size distribution of the formulation of Example 3, processed according to the flow chart of Figure 4, as measured with a Malvern Mastersizer 2000.
- Curve a) is the temperature/time profile
- Curve b) is the viscosity versus time for a non spray-cooked sample
- Curve c is the viscosity versus time for a spray-cooked sample.
- the left Y-axis refers to the viscosity
- the right Y-axis to the temperature.
- Time is plotted on the x-axis.
- Figure 7 Flow chart of a process for the manufacture of a neutral protein formula (16 g/100 ml) based on whey protein (Example 4).
- Example 1 Acidic whey protein composition (12 g/100 ml) (composition Al)
- FIG. 1 A flow chart of the process is shown in Figure 1.
- the protein WPC powder of Lactalis, Prolacta 80
- carbohydrates and minerals were dispersed in water and the solution was set to pH 4.0 using 50 % lactic acid.
- the oil was blended into the product and the pre-emulsion was homogenised at 40 0 C in a 2-stage homogenizer at a pressure of 550/50 bar.
- the product was then atomised into the spray-cooking chamber and instantly heated to 110 0 C by mixing with steam and held at this temperature for approximately 50 msec. Subsequently, the product was flash-cooled to 50 0 C and pumped into a holding tank.
- the final pH of the product was adjusted to pH 4.0 and the product was then UHT pasteurised at 92°C for 30 sec and filled into 200 ml bottles.
- the product was liquid, with a viscosity of 150 mPa.s at 20°C at a shear rate of 100 s "1 .
- the product had a smooth mouth feel. This is confirmed by the particle size distribution (Figure 2), which shows that the spray-cooking has little effect on the particle size.
- the spray-cooking step appears to have stabilised the protein aggregates against further aggregation: the particle size after UHT pasteurisation is nearly unchanged compared to the spray cooked intermediate product.
- the average particle diameter as obtained from static light scattering (Malvern Mastersizer 2000), d[4,3], after homogenisation ( a), spray-cooking (b) and UHT pasteurisation (c) were 7.7 ⁇ m, 6.0 ⁇ m and 5.4 ⁇ m, respectively.
- Example 2 Acidic whey protein composition (12 g/100 ml) (composition A2)
- composition A2 was made according to the process of Example 1.
- WPI powder from Fonterra (LGI 895) was used as the protein source.
- the final product was liquid, with a very low viscosity of 15 mPa.s at a shear rate of 100 s "1 .
- the product had a smooth mouth feel.
- the average particle diameter as obtained from static light scattering (Malvern Mastersizer 2000), d[4,3], after UHT pasteurisation was 5.7 ⁇ m.
- Composition A5 was made in a similar way as composition A2.
- Example 3 Acidic whey protein composition (16 g/100 ml) (composition A3)
- a flow chart of the process is shown in Figure 4.
- the protein (WPI) (Bipro®, Davisco), carbohydrates and minerals were dispersed in water and the solution was set to pH 4.1 using citric acid.
- the oil was blended into the product and the pre-emulsion was homogenised at 40 0 C in a 2-stage homogenizer at a pressure of 550/50 bar.
- the product was then atomised into the spray-cooking chamber and instantly heated to 120 0 C by mixing with steam and held at this temperature for approximately 50 msec. Subsequently, the product was flash-cooled to 50 0 C and pumped into a holding tank.
- the final pH of the product was adjusted to pH 4.1 and the product was split in two batches.
- the spray-cooking step appears to have stabilised the protein aggregates against further aggregation: the particle size after UHT and retort pasteurisation is nearly unchanged compared to the spray-cooked intermediate product.
- the average particle diameter as obtained from static light scattering (Malvern Mastersizer 2000), d[4,3], after homogenisation (a), spray-cooking (b) and UHT pasteurisation (c) or retorting (d) were 4.7 ⁇ m, 3.7 ⁇ m, 3.9 ⁇ m or 3.8, respectively. It was observed that the mineral levels had only small effects on the final product characteristics like particle size, viscosity and shelf life stability.
- non spray-cooked and spray-cooked emulsions were subjected to the same heat treatment in a rheometer. Samples were heated up to 90°C, kept at 90° for 10 minutes and cooled back while measuring the viscosity. The temperature versus time curve is given in Figure 6, curve (a). As can be seen, the non spray-cooked emulsion (b) shows a large jump in viscosity when the temperature exceeds 80°C, while the viscosity of the spray-cooked emulsion (c) largely stays unaffected, illustrating the stabilizing effect of the method according to the invention.
- FIG. 7 A flow chart of the process is shown in Figure 7.
- the whey protein isolate (WPI) (Bipro®, Davisco) and sucrose were dispersed in demineralised water and the solution was adjusted to pH 7.5 using a 10% KOH solution. Oil was blended into the product and the pre-emulsion was homogenised at 40 0 C in a 2-stage homogenizer at a pressure of 550/50 bar. The product was then atomised into the spray-cooking chamber and instantly heated to 170 0 C by mixing with steam and held at this temperature for approximately 100 ms. Subsequently, the product was flash-cooled to 55°C and aseptically filled into aseptic 200 ml bottles.
- the product was liquid, with a viscosity of 97 mPa.s at a shear rate of 100 s "1 .
- the product had a smooth mouth feel. This is confirmed by the particle size distribution which shows that the spray-cooking has little effect on the particle size. If anything, the particles become smaller during the process.
- the average particle diameter as obtained from static light scattering (Malvern Mastersizer 2000), d[4,3], after homogenisation (a), spray-cooking (b) were 0.48 ⁇ m and 0.29 ⁇ m, respectively.
- the method according to the invention is compared with several other methods commonly employed in the field of nutritional compositions using the ingredients of composition Al.
- a summary is given in Table 2.
- Yoghurt like products with a pH less than pH 4.2 require a pasteurization step (either 90 0 C, 15 min or 92°C, 30 sec) for long shelf life products.
- the temperature required for pasteurization is well above the denaturation temperature of whey proteins.
- Denatured whey proteins are reactive molecules capable of aggregate formation.
- the same formulation can form a gel or a liquid product depending on the heating conditions. For example, slow heating in a rheometer, tube heat exchanger, or during gentle mixing in the retort results in a gelled product.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pediatric Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- General Health & Medical Sciences (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dairy Products (AREA)
Abstract
The present invention relates in general to a shelf-stable liquid enteral composition for providing nutrition, either as a supplement, or as a complete nutrition, with a high protein content of a non-hydrolysed globular protein, in particular a whey protein.
Description
HIGH PROTEIN LIQUID ENTERAL NUTRITIONAL COMPOSITION
FIELD OF THE INVENTION
This invention is concerned with a method for the heat-treatment of a non-hydrolysed globular protein, the non-hydrolysed heat-treated globular protein per se, a shelf-stable liquid enteral nutritional composition with a high content of non-hydrolysed globular protein as a major protein source, processes for the preparation thereof and use of said liquid enteral nutritional composition for the treatment of persons in need thereof.
BACKGROUND OF THE INVENTION Clinical problem
Some patients need nutrition, either as a supplement, or as a complete nutrition, in the smallest volume of liquid.
These patients can be cachectic patients or persons suffering from end-stage AIDS, cancer or cancer treatment, severe pulmonary diseases like COPD (chronic obstructive pulmonary disease), tuberculosis and other infection diseases or persons that experienced severe surgery or trauma like burns. Furthermore, persons suffering from disorders in the throat or mouth such as oesophageal cancer or stomatitis and persons having problems with swallowing like dysphagic persons, require special liquid, low-volume nutrition. Also, persons just suffering from reduced appetite or loss of taste, will benefit from low- volume, preferably liquid, food.
These patients can also be elderly persons, in particular frail elderly and elderly at risk of becoming frail. In this regard, although an elderly person's energy needs may be reduced, their ability to consume products may also be diminished. For example, they may have difficulty consuming a product due to, e.g., swallowing difficulties, or due the too large amount of product they need to consume to meet the daily intake of nutrients. Hence, compliance is not optimal, and often, the intake is suboptimal, leading to suboptimal nourishment, and in the end, to malnutrition.
In this respect, it is submitted that in the context of this application, an elderly person is a person of the age of 50 or more, in particular of the age of 55 or more, more in particular of the age of 60 or more, more in particular of the age of 65 or more. This rather broad definition takes into account the fact that the average age varies between different populations, on
different continents, etc. Most developed world countries have accepted the chronological age of 65 years as a definition of 'elderly' or older person (associated with the age at which one may begin to receive pension benefits), but like many westernized concepts, this does not adapt well to e.g. the situation in Africa. At the moment, there is no United Nations (UN) standard numerical criterion, but the UN agreed cut-off is 60+ years to refer to the older population in Western world. The more traditional African definitions of an elder or 'elderly' person correlate with the chronological ages of 50 to 65 years, depending on the setting, the region and the country.
The aforementioned groups of patients may be extremely sensitive to food consistency and to the organoleptic properties of the product such as, for instance viscosity, mouth feel, taste, smell and colour. Also, patients such as cachectic patients, typically suffer from extreme weakness which often prevents them from sitting in a vertical position and from their ability to drink the food from a carton or even to suck it from a straw. These patients benefit well from liquid low-volume enteral compositions with a high content of nutrients. Therefore, the problem underlying the present invention is to provide a shelf-stable liquid enteral composition for providing nutrition, either as a supplement, or as a complete nutrition, with a high content of non-hydro lysed globular protein as major protein source, in particular whey proteins, in the smallest volume of liquid, and which supports nutrition and well-being in the different patient groups mentioned above. In the context of the current application, enteral means any form of administration that involves any part of the gastrointestinal tract, i.e. by mouth (orally), by gastric feeding tube, duodenal feeding tube, or gastrostomy, and rectally.
Technical problem Major technical difficulties exists in producing such a shelf-stable liquid enteral nutritional composition with a high content of non-hydrolysed globular proteins, in particular non- hydrolysed whey proteins.
For example, increasing the amount of proteins leads to precipitation and sedimentation of proteins and other ingredients, such as lipids and carbohydrates, which imparts nutrient intake.
Concentrating liquids also increases the chance of undesired interactions between ingredients which reduces stability, especially during heating and long-term storage.
Furthermore, increasing the protein content in a nutritional liquid composition may increase the overall viscosity of the composition. This can make the liquid nutritional composition difficult to consume or administer, and can also diminish the taste of the nutritional composition. These phenomena often follow non-linear kinetics and the problems quickly increase in magnitude when the concentration of ingredients is increased above 28 weight%. Therefore, many of the commercial shelf-stable liquid products that are currently available have intact protein levels below about 9 g per 100 ml of product. A known solution to the problem how to increase the protein levels to a higher level without imparting viscosity is replacing part of the total protein by peptides or free amino acids. However, this seriously decreases taste appreciation and therefore voluntary intake of the nutritional composition by the patient group.
On the other hand, many concentrates like condensed milks suffer from an incomplete nutrient profile, too high lactose levels, sticky mouth-feel, high viscosity, extreme sweetness and a high osmotic value, which is not appreciated by the consumer and increases rapidly feelings of fullness and satiety after consumption. This makes that the urge to consume more volume deteriorates rapidly once a small amount of the product has been consumed.
EP 0 486 425 A2 (Sandoz Nutrition, published 20 May 1992) discloses a liquid nutritional composition comprising 3.9 weight% of WPC having an energy density of 1.0 kcal/ml.
EP 0 747 395 (Nestle S.A, published 11 December 1996) discloses a product for treating renal patients having an energy density of 1.6-2.25 kcal/ml and comprising free amino acids and whey proteins, wherein the ratio of essential amino acids to non-essential amino acids is 2- 4:1. By using free amino acids, the amino acid composition is improved without increasing the viscosity. However, the taste is not acceptable for cachectic persons or other persons which have difficulties in eating the proper volume of food. The amount of protein is about 3 to 4 g/100 ml ofproduct.
EP 1 314 361 (Nestec S.A., published 28 May 2005) discloses a nutritionally complete calorically dense formula comprising maximum 8 g/100 ml intact whey protein using WPI as a source of whey (Example 1). The whey solution is acidified to a pH of 3.0, UHT treated at
148 0C for 5 seconds followed by a readjustment of the pH to 6.8. This solution is
subsequently mixed with the usual ingredients (lipids, carbohydrates, minerals) to provide a nutritional composition.
WO 2007/110411 and WO 2007/110421 (Nestec S.A., published October 4, 2007) disclose heat-treated whey protein micelles, obtained by a process which comprises a pH adjustment and a heat-treatment between 700C and 95 0C.
SUMMARY OF THE INVENTION
In one embodiment, the present invention relates in general to a shelf-stable liquid enteral composition for providing nutrition, either as a supplement, or as a complete nutrition, with a high protein content of a non- hydro lysed globular protein, in particular a whey protein.
In one embodiment, the present invention provides a shelf-stable liquid enteral nutritional composition based mainly on non-hydrolysed globular proteins, designed to meet the nutritional needs of persons in need thereof, in particular elderly, persons recovering from certain disease states, and malnourished persons . The composition provides an increased amount of proteins per unit volume while providing a sufficiently low viscosity to allow the composition to be easily consumed orally or be administered by tube. In addition, the taste of the composition is not diminished in comparison with a less concentrated composition based on non-hydrolysed whey proteins.
To this end, in a first embodiment of the present invention, a liquid enteral nutritional composition is provided comprising 9 to 20 g of non-hydrolysed globular protein per 100 ml of the composition. In particular, said globular protein is a whey protein.
In a second embodiment, the present invention concerns a method of providing nutrition to a person in need thereof, in particular elderly, persons recovering from certain disease states, and malnourished persons, comprising the steps of administering to said person the nutritional composition according to the present invention.
In a third embodiment, the present invention concerns a process for the heat-treatment of non- hydrolysed globular proteins, to obtain heat-treated non-hydrolysed globular proteins with unique properties. In particular, said heat-treated non-hydrolysed globular protein is a whey protein. The unique properties allow not only the manufacture of a nutritional composition comprising 9 to 20 g of heat-treated non-hydrolysed globular per 100 ml of the composition, but the
unique heat-treated non-hydrolysed globular protein is suitable for use in any nutritional composition comprising these unique heat-treated globular proteins as a protein source in any concentration. Therefore, in a fourth embodiment, the present invention concerns the unique heat-treated non-hydrolysed globular proteins per se, obtainable by the process according to the invention, and any product, formulation or composition comprising said heat-treated globular proteins, in particular whey proteins.
The invention will now be further elucidated by describing a number of embodiments of the present invention.
DETAILED DESCRIPTION OF THE INVENTION Globular Proteins
The invention is generally concerned with globular proteins. Globular proteins may be single chains, two chains or more chains which interact in the usual ways or there may be portions of the chains with helical structures, pleated structures, or completely random structures. Globular proteins are relatively spherical in shape as the name implies. They are distributed in both plant and animal tissues. For instance, albumins can be found in blood (serum albumin), milk (lactalbumin), egg white (ovalbumin), lentils (legumelin), kidney beans (phaseolin), and wheat (leucosin). Globulins can be found in blood (serum globulins), muscle (myosin), potato (tuberin), Brazil nuts (excelsin), hemp (edestin), whey (lactoglobulins, immunoglobulins, and lactoferrins), pea and lentils (legumin, vicilin), and soy. Also, many enzymes and other vegetable proteins are globular proteins.
More specifically, the invention is concerned with pea, soy and whey proteins, more in particular with whey proteins.
Whey Proteins
One of the most superior classes of food protein is whey protein. It is known for its excellent amino acid profile, high cystein content, rapid digestion, and interesting bioactive proteins (lactoglobulins, immunoglobulins, and lactoferrins). Nutritionally speaking, whey protein is known as a naturally complete protein because it contains all of the essential amino acids required in the daily diet. It is also one of the richest sources of branched chain amino acids (BCAAs, in particular leucine) which play an important role in muscle protein synthesis.
Moreover, some of the individual components of whey protein have been shown to prevent viral and bacterial infection and modulate immunity in animals. Whey protein is the preferred choice of proteins to treat persons suffering from sarcopenia, but is also suitable for healthy persons, such as sportsmen and active elderly. As a source of whey protein to be used in the present invention, any commercially available whey protein source may be used, i.e. whey obtained by any process for the preparation of whey known in the art, as well as whey protein fractions prepared thereof, or the proteins that constitute the bulk of the whey proteins being β-lactoglobulin, α-lactalbumin and serum albumin, such as liquid whey, or whey in powder form, such as whey protein isolate (WPI) or whey protein concentrate (WPC). Whey protein concentrate is rich in whey proteins, but also contains other components such as fat, lactose and glycomacroprotein (GMP), a caseine- related non-globular protein. Typically, whey protein concentrate is produced by membrane filtration. On the other hand, whey protein isolate consists primarily of whey proteins with minimal amounts of fat and lactose. Whey protein isolate usually requires a more rigorous separation process such as a combination of micro filtration and ultra- filtration or ion exchange chromatography. It is generally understood that a whey protein isolate refers to a mixture in which at least 90 weight % of the solids are whey proteins. A whey protein concentrate is understood as having a percentage of whey proteins between the initial amount in the by-product (about 12 weight%) and a whey protein isolate. In particular, sweet whey, obtained as a by-product in the manufacturing of cheese, acid whey, obtained as a by-product in the manufacturing of acid casein, native whey, obtained by milk microfiltration or rennet whey, obtained as a by-product in the manufacturing of rennet casein, may be used alone or in combination as source of globular whey proteins.
Furthermore, whey proteins may originate from all kinds of mammalian animal species, such as, for instance cows, sheep, goats, horses, buffalo's, and camels. Preferably, the whey protein is of bovine origin.
Preferably, the whey protein source is available as a powder, preferably the whey protein source is a WPC or WPI.
Whey protein isolate consists mainly of a mixture of β-lactoglobulin (about 65 weight%), α- lactalbumin (about 25 weight%) and serum albumin (about 8 weight%). These proteins are globular proteins that are sensitive to aggregation in the denaturated state. The denaturation temperature of β-lactoglobulin is pH-dependent; at pH 6.7, irreversible denaturation occurs when the protein is heated at temperatures above 65°C. In the denaturated state, a free thiol
group is exposed. This free thiol group can initiate inter -protein disulfide interactions leading to a polymerization reaction resulting in aggregate formation. Also two disulfide bridges, present in native β-lactoglobuline, are involved in the polymerization reaction and also other sulphur containing groups including cysteine residues are thought to play a role. α-Lactalbumin also has a denaturation temperature of about 65°C . Since α-lactalbumin does not have a free thiol group (only four disulfide bridges), solutions of pure α-lactalbumin are not irreversibly denaturated under most processing conditions. However, in the presence of β- lactoglobulin, as is the case in e.g. a whey protein concentrate or isolate, α-lactalbumin is more sensitive to irreversible denaturation through the formation of α-lactalbumin/β- lactoglobulin complexes in which also disulfide bridges in β-lactoglobuline and α-lactalbumin are involved via interchange reactions. Also the circumstance that α-lactalbumin contains cystein residues is considered to contribute to a certain sensitivity to irreversible denaturation.
Denaturated β-lactoglobulin and α-lactalbumin are both sensitive to calcium; this is particularly the case in the pH range of about 5 to about 8 where the protein carries a neutral to net negative charge. At pH 4, the protein carries a net positive charge and is less sensitive to calcium-induced aggregation.
The size, shape and density of the protein aggregates are influenced by a number of environmental and processing parameters including temperature, heating rate, pressure, shear, pH and ionic strength. Depending on the combination of these parameters, the aggregates may form a space-filling network (gel), fibrils or compact micro-particles. For example microparticulated whey can be formed under specific ionic strength and shear conditions. These particles have a compact structure, a high intrinsic viscosity and a low specific volume. Further, it is known that a relationship exists between aggregates size and heating temperature for microparticulated whey produced under shear conditions. Microparticulated whey protein has received a lot of interest lately for application as a fat replacer or viscosity enhancer for yoghurt.
One of the major problems encountered with the production of liquid ready-to-use compositions containing globular proteins in general, and whey proteins in particular, is their limited processability and heat-sensitivity. As these proteins are heated above their denaturation temperature in a sterilization process, they unfold and are transformed into a reactive state, polymerize into aggregates or gels. As a consequence, the heat-treated liquid composition exhibits unwanted sensorial attributes like chalkiness, sandiness, lumpiness. Besides, the shelf life of these products is limited in that sediment and/or cream layers are
formed soon after production. In a composition with a high globular protein content, in particular whey, these instabilities are even more pronounced and result in products with an unwanted high viscosity and extensive fouling and blocking of the UHT heating equipment .
Surprisingly, the inventors ha ve now found that it is possible to prepare a pasteurized or sterilized liquid enteral nutritional composition having a long shelf life by means of a method wherein a composition that comprises mainly globular proteins as a protein source, in particular whey proteins, is subjected to a specific heat -treatment that comprises the steps of converting the composition into an aerosol and quickly heating and cooling said aerosol to obtain a composition of unique heat-treated globular proteins, in particular whey proteins. Without being bound (or restricted) to any theory, it is believed that raising the temperature quickly to a temperature well above the denaturation temperature of the whey protein, leads to a near- instantaneous denaturation of whey protein. The thiol group of β-lactoglobulin, the main constituent of whey protein, is being exposed and te rmination reactions forming disulfide bridges dominate initially after heating. As a result, small, compact whey protein particles are formed which are largely inert in any further heat-treatment. On the contrary, in a heat-treatment just above the denaturation temperature of the whey, the aggregation reaction is limited by the rate of unfolding of the protein, leading to extensive polymerization and voluminous protein aggregates. Also , when the whey is heated to high temperatures (i.e. far above the protein denaturation temperature, for example at 1100C) via a slow heating process, i.e. a process in which the temperature of the protein solution is raised gradually, for example 0.1 to 2°C per second, using e.g. retort, plate or tubular heat exchangers, the whey exhibits extensive polymerization during heating up when process temperatures pass the temperature window just above the denaturation temperature of the whey protein. As a result, the product is too thick, lumpy, sandy and extensive fouling is observed in the heating apparatus. Thus surprisingly, it was found that the time for whey proteins to be spent in a temperature window just above the denaturation temperature, should be minimized.
Method of heat treatment
The non-hydrolysed globular proteins, in particular whey proteins, are subjected to a heat- treatment, comprising the consecutive steps of: a) adjusting the pH of an aqueous composition comprising non-hydrolysed globular proteins to a value of between about 2 and 8;
b) converting the composition comprising non-hydrolysed globular proteins obtained in step a) into an aerosol; c) subjecting the aerosol obtained in step b) to a temperature of 100 to 1900C during a time of about 10 to 300 milliseconds ; d) flash-cooling the heat-treated aerosol obtained in step c) to a temperature below 85 °C to obtain an aqueous solution comprising heat-treated globular proteins.
It is emphasized that the aqueous composition comprising non-hydrolysed globular proteins may contain, next to non-hydrolysed globular proteins, in particular whey, any other nutritional ingredients, such as other proteins, amino acids, fat, carbohydrates, fibers, minerals, vitamins, and the like, and that these ingredients may be present when subjecting the aqueous composition to the method according to the invention, in particular step b).
In one embodiment, the pH of the aqueous composition of non-hydrolysed globular proteins in step a) is about 2 to 5. More preferably, the pH of the aqueous composition of non- hydrolysed globular proteins in step a) is about 4. In yet another embodiment, the pH of the aqueous composition of non-hydrolysed globular proteins in step a) is about 6 to 8. More preferably, the pH of the aqueous composition of non- hydrolysed globular proteins in step a) is about 7.
Preferably, said globular proteins are whey proteins.
In one embodiment, the aerosol obtained in step b) is subjected to a temperature of 110 to 1800C, during a time of about 20 to 200 milliseconds, more preferably 40 to 150 milliseconds, more preferably 80 to 120 milliseconds. In another embodiment, the aerosol obtained in step b) is subjected to a temperature of 1100C, during a time of about 20 to 200 milliseconds, more preferably 40 to 150 milliseconds, more preferably 80 to 120 milliseconds. In yet another embodiment, the aerosol obtained in step b) is subjected to a temperature of 1700C, during a time of about 20 to 200 milliseconds, more preferably 40 to 150 milliseconds, more preferably 80 to 120 milliseconds.
In one embodiment, in step a) the pH of an aqueous composition of non-hydrolysed whey proteins is adjusted to a value of about 4 (acid whey solution), and the aerosol obtained in step b) is subjected to a temperature of 1100C, during a time of about 20 to 200 milliseconds, more preferably 40 to 150 milliseconds, more preferably 80 to 120 milliseconds.
In another embodiment, in step a) the pH of an aqueous composition of non-hydrolysed whey proteins is adjusted to a value of about 7 (neutral whey solution), and the aerosol obtained in
step b) is subjected to a temperature of 1700C, during a time of about 20 to 200 milliseconds, more preferably 40 to 150 milliseconds, more preferably 80 to 120 milliseconds.
In one embodiment, in step c), the conversion of the composition of non-hydrolysed globular proteins obtained in step a) into an aerosol is done using a spray nozzle, as described below in detail.
In one embodiment, step d) is performed by transporting the aerosol into a vacuum chamber (flash-cooling) to remove an amount of water by evaporation, equivalent to the amount of steam used and the product is cooled by indirect cooling to a temperature of less than about 85°C, preferably less than about 600C. This method allows fast cooling and quick removal of volatiles (i.e. steam). The cooling preferably takes place nearly instantaneously, i.e. in a time window preferably of milliseconds.
It is without saying that any of the aforementioned preferred values (pH, temperature and time) and ranges thereof for each of the steps a), b), c) and d) may be combined in an intelligent manner, without departing from the scope of the invention. A similar, albeit fundamentally differently operated method has been disclosed in EP 1 351 587 (NV Nutricia). This document discloses a sterilization process using a spray-cooking apparatus, wherein a liquid product with a solids content of more than 55 weight%, comprising 10.4 g/100 ml of whey and 2.4 g/100 ml of casein, is subjected to steam pressure of 14 bar (195°C) for a time of less than 20 milliseconds. At these conditions, the liquid product is atomized, pasteurized and dried in a spray tower, thus providing a solid powder with less than 4% of moisture. The product is obtained as a solid, not as a liquid, and at different conditions of temperature and residence time. The pH is not given, but it may be assumed that the pH was neutral. Although a similar apparatus was used in the examples of the present application, the apparatus was operated differently, the major difference being that a liquid composition is obtained and that the aerosol is subjected to heat for a much longer time.
Apparatus
The apparatus to carry out the invention may be selected by the skilled person based on the steps described above. Basically, the apparatus to carry out the invention comprises a nozzle for atomizing the composition (step b), a chamber to heat the aerosol (step c), and a chamber to cool the heated aerosol (step d). Preferably, the heating is done by mixing the aerosol with
steam of a certain temperature (and at a certain steam pressure). When using steam, the apparatus may comprise a nozzle and a mixing chamber. A mixing chamber generally comprises one or more inflow openings for steam flows and for product flows, in which a product flow may optionally be premixed with a part of the steam. It may be preferable to select the mixing chamber such that only one product flow is atomized with one steam flow, since this simplifies the cleaning of the mixing chamber after use.
A schematic representation of a suitable nozzle for atomization according to the invention is shown in EP 1351587, Fig. 1, in which a nozzle with mixing chamber is shown. Said Fig.l is included herein by reference. It turns out that a nozzle with mixing chamber can be very effectively used for the heat treatment of a product. A suitable mixing chamber is generally characterized in that steam and atomized product to be treated are mixed, while the volume throughput of the steam will be much greater than that of the atomized product to be treated and the residence time of the atomized product is sufficiently to obtain the desired heat- treated globular protein. The volume ratio between the steam flow and the product flow may range between, for instance, about 20:1 and 150:1. It is important that the pressure in the mixing chamber is higher than in the space to which the atomized product is passed.
The form and size of the inflow openings for the steam flow (1) and the flow of the product in liquid form (2) in the mixing chamber and their mutual position are selected such that intensive mixing takes place between product and steam. It is noted that the inflow openings can be placed such that the steam flow and the product flow enter the mixing chamber in substantially parallel direction. This may take place in both a horizontally, vertically and diagonally manner. However, it is also possible that the steam flow and the product flow enter the mixing chamber at different angles, for instance a vertical steam flow and a horizontal product flow. The inflow openings are further arranged such that the product is atomized in small droplets, which after a short residence time in the mixing chamber (4) leave the mixing chamber through an outflow opening (5), for instance to a cooling chamber (6). The inflow opening(s) for the steam flow preferably contain a steam distribution plate (3). By changing the dimensions of the mixing chamber and/or the outflow opening(s) in the manner known to those skilled in the art, the average residence time and particle size of the atomized droplets can be varied. To set a suitable residence time in the mixing chamber is a simple matter of optimization for the skilled person and depends at least on the temperature and pressure in the mixing chamber.
The mixing is preferably realized by contacting the atomized product flow and the steam flow close to the inflow opening of the product in the mixing chamber and bringing the steam at high speed around the atomized product. In a preferred embodiment, such a mixing takes place by bringing the steam near the product concentrically around the inflow opening of atomized product in the mixing chamber. The product flow to steam flow ratio can be varied in a ratio of 1.6 to 10 kg product in liquid form per kg steam. Very good results are realized at a wet product flow to steam flow ratio of 2.4 to 8 kg product in liquid form per kg steam.
In principle, any type of mixing chamber is suitable in which steam and product can be mixed and atomized. Very suitable for mixing and atomizing a product-steam mixture according to the invention is a nozzle such as "two-fluid" type nozzle, an example of which is described in EP 0438783, Fig. 1 . This nozzle contains a small chamber at the end of a product line in which steam and product are combined. To increase the capacity, more nozzles can be used in a parallel arrangement.
The temperature of the supplied saturated or superheated steam in the method according to the invention is preferably in the range of 100 and 1900C, more preferably between 100 and 1800C, still more preferably between 100 and 170 0C. In general, the temperature in the mixing chamber will be maintained at the desired level through the steam, although it is also possible that the mixing chamber itself is heated by another heat source.
Good results are obtained when introducing the steam into the mixing chamber at a steam pressure of 1.5 to 10 bar, and in particular at a steam pressure of 1.8 to 8.2 bar, in mixing chambers about 1 to 20 cm in length. This pressure is preferably measured just before the steam is introduced into the mixing chamber via a spray nozzle.
Preferably, the particle size (aggregate size) of the flash-cooled aerosol (obtained in step d) is less than about 30 μm, more preferably less than about 10 μm, still more preferably less than 5 μm, and most preferably less than 1 μm. At particle diameters above 30 μm, the nutritional composition may start to taste sandy, which is not favoured.
Depending on the temperature/time combination, the method according to the invention may not provide sufficient pasteurization or sterilization. For instance, 100 milliseconds at 1100C does not provide sufficient microbial sterility for a neutral product. However, 100 milliseconds at 1700C would provide sufficient sterility.
In one embodiment, the product obtained from step d) is further pasteurized using conventional equipment such as a plate or tubular heat exchanger, scraped surface heat
exchanger or a retort to give the final product. Most excellent results are obtained when using a plate heat exchanger. The invention therefore also relates to the above described method according to the invention, comprising steps a), b), c) and d), subsequently comprising a pasteurization step using a plate heat exchanger. The plate heat exchanger is preferably operated at 92 0C for 30 seconds.
In another embodiment, a sterile product is obtained from step d) or from the above mentioned subsequent pasteurization step, which can be filled aseptically in aseptic containers in a further process step.
Nutritional composition
Surprisingly, this invention makes it possible to produce a liquid enteral nutritional composition with a high content of non-hydrolysed globular protein , in particular whey protein, with a long shelf life and with a low viscosity.
In the context of this application, "non-hydrolysed" proteins is equivalent to "intact" proteins, meaning that the proteins have not been subjected to an hydrolysis process. However, minor amounts of hydrolysed proteins may be present in the source of non-hydrolysed proteins, or may be added to the formulation, such as additional amino acids, such as, for example leucine, isoleucine, and the like. In this context, "minor" should be understood as an amount of about 20 weight% or less, for example of about 10 weight% or less. The term "about" should be interpreted as a deviation of plus or minus 10 % of the given value.
Hence, in an embodiment of the invention, a liquid enteral nutritional composition comprising 9 to 20 g of non-hydrolysed globular proteins per 100 ml of the composition is provided. Preferably, the globular proteins are whey proteins. In another embodiment, the amount of non-hydrolysed globular proteins are 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 gram per 100 ml of the composition, or any value in between the aforementioned values.
In one embodiment, the pH of the liquid enteral nutritional composition is about 2 to about 8. In another embodiment, the pH is about 2, 3, 4, 5, 6, 7, or 8 or any value in between the aforementioned values.
In a specific embodiment of the composition according to the invention, the composition is acidic (yoghurt-like or juice-like) with a pH of about 4. Acidification may be achieved by any method known to the skilled person, such as the addition of an acid (such as, for instance
lactic acid, citric acid, phosphoric acid) or through fermentation. The thus obtained composition has a pleasant mild acidic taste which can be flavoured perfectly with a fruity flavour.
In a further specific embodiment of the invention, the composition has a neutral pH (i.e. a pH of about 7). The thus obtained composition has a pleasant taste which may optionally be flavoured with e.g. vanilla, chocolate, caramel, banana, strawberry.
According to another embodiment of the present invention, the protein provides 10 % to 50 %, preferably at least 15 %, more preferably at least 20 %, at least 25 %, at least 30 % of the total energy content of the composition. The % of total energy is also abbreviated as En%; En% is thus short for energy percentage and represents the relative amount that a constituent contributes to the total caloric value of the composition. The high levels of protein are beneficial for patients who may not be physically capable of receiving a large volume, for example, fluid restricted patients. Such patients can be given a reduced level of fluid while still receiving a required amount of nutritional support per day. In the context of this application, the term "at least" also includes the starting point of the open range. For example, an amount of "at least 95 weight%" means any amount equal to 95 weight % or above.
In one embodiment of the present invention, the composition has an energy density of at least 0.36 kcal/ml, preferably at least 1.0 kcal/ml, preferably at least 1.5 kcal/ml, preferably at least 2.0 kcal/ml, more preferably at least 2.4 kcal/ml. Although the composition has a high energy density, it also has a sufficiently low viscosity to allow it to be consumed by persons that may have difficulty swallowing products or those that are tube fed.
In one embodiment of the present invention, the amount of whey proteins in the liquid nutritional composition according to the invention is at least 85 weight%, more preferably at least 90 weight %, more preferably at least 95 weight% of the total protein present in the liquid nutritional composition.
In a further embodiment of the present invention, the composition may comprise up to about 40 weight% of a non-globular protein, such as casein, caseinate, micellar casein isolate and the like, and any mixture thereof, preferably less than or equal to 20 weight%, more preferably less than or equal to 10 weight% of the total protein present in the liquid nutritional composition.
In one embodiment of the present invention, the composition may comprise a free amino acid, or a mixture of free amino acids, up to 5 g/ 100ml, more preferably less than 2g/100 ml, more preferably less than 1 g/100 ml, most preferably less than 0.5 g/100 ml
The composition according to the invention is designed to either supplement a person's diet or to provide complete nutritional support. Hence, the composition according to the invention may further comprise at least fat and/or carbohydrate and/or a source of vitamins and minerals and/or a source of prebiotics. Preferably, the composition according the invention is a nutritionally complete composition.
Fat
In one embodiment of the present invention, the liquid nutritional composition according to the invention further comprises fat, said fat providing between 20 to 40 % of the total energy content of the composition. For a 1.6 kcal/ml composition, this amounts to 32 to 64 kcal per 100 ml. For a 2.4 kcal/ml composition, this amounts to 48 to 96 kcal per 100 ml. The fat may include medium chain triglycerides (MCT, mainly 8 to 10 carbon atoms long), long chain triglycerides (LCT) or any combination of the two types. MCTs are beneficial because they are easily absorbed and metabolized in a metabolically-stressed patient. Moreover, the use of MCTs will reduce the risk of nutrient malabsorption. LCT sources, such as canola oil, rapeseed oil, or corn oil are preferred because they can reduce immune suppression associated with certain types of fatty acids concentrated in the body.
Preferably, the fat comprises 30 to 60 weight% of animal or algal fat, 40 to 70 weight% of vegetable fat and optionally 0 to 20 weight% of MCTs based on total fat of the composition. The animal fat preferably comprises a low amount of milk fat, i.e. lower than 6 weight%, especially lower than 3 weight%. In particular, a mixture of corn oil, egg oil, and/or canola oil and specific amounts of marine oil are used. Egg oils, fish oils and algal oils are a preferred source of non-vegetable fats. Especially for compositions that are to be consumed orally, in order to prevent formation of off-flavours and to decrease a fishy after-taste, it is recommended to select ingredients that are relatively low in docosahexanoic acid (DHA), i.e. less than 6 weight%, preferably less than 4 weight% of the fat. Marine oils containing DHA are preferably present in the composition according to the invention in an amount lower than 25 weight%, preferably lower than 15 weight% of the fat. On the other hand, inclusion of eicosapentanoic acid (EPA) is highly desirable for obtaining the maximum health effect. The
amount of EPA ranges preferably between 4 weight% and 15 weight%, more preferably between 8 weight% and 13 weight% of the fat. The weight ratio EPA:DHA is advantageously at least 6:4, for example between 2:1 and 10:1.
Also, the liquid nutritional composition according to the invention may beneficially comprise an emulsifier. Commonly known emulsifiers may be used, such as lecithin, and generally the emulsifier contributes to the energy content of the fat in said composition.
Carbohydrates
In one embodiment of the present invention, the liquid nutritional composition according to the invention further comprises carbohydrate, said carbohydrate providing between 30 to 60 % of the total energy content of the composition. Preferably, the carbohydrate provides at least 40 % of the total energy content of the composition according to the invention.
The composition of the carbohydrate preferably is such that high viscosities, excessive sweetness, excessive browning (Maillard reactions) and excessive osmolarities are avoided. Acceptable viscosities and osmolarities may be achieved by adjusting the average chain length (average degree of polymerisation, DP) of the carbohydrates between 1.5 and 6, preferably between 1.8 and 4. In order to avoid excessive sweetness, the total level of sucrose and fructose is less than 52 % and preferably less than 40 % of the weight of the carbohydrate, especially of the digestible carbohydrate. Long-chain digestible carbohydrates such as starch, starch fractions and mild starch hydrolysates (DP > 6, DE < 20), may also be present, preferably in an amount of less than 25 weight%, especially less than 15 weight% of the carbohydrate, and less than 6 g/100 ml, preferably less than 4 g/100 ml of the total liquid enteral composition according to the invention.
In one embodiment of the present invention, the carbohydrate includes maltodextrose with a high DE (dextrose equivalent). In one embodiment the carbohydrate includes maltodextrose with a DE of > 20, preferably > 30 or even > 40, such as a DE of about 47. In one embodiment of the present invention, the carbohydrate includes maltodextrose with a high DE in an amount of at least 35 weight%, preferably at least 50 weight%, preferably at least 65 weight%, preferably at least 90 weight% of the total weight of carbohydrate. In one embodiment of the present invention, the carbohydrate includes maltodextrose with a low DE of 2 to 20. In one embodiment of the present invention, the carbohydrate includes maltodextrose with a low DE of 2 to 10, preferably with a low DE of about 2. In one
embodiment of the present invention, the carbohydrate includes maltodextrose with a low DE in an amount of less than 35 weight%, preferably less than 20 weight%, preferably less than 10 weight% of the carbohydrate. Maltodextrose with a low DE may also be referred to as maltodextrine. In another embodiment of the present invention, the carbohydrate includes maltodextrose with a high DE, preferably a DE of > 20, preferably > 30 or even > 40, most preferably a DE of about 47 in combination with maltodextrose with a low DE, preferably a low DE of 2 to 20, more preferably a low DE of 2 to 10, most preferably with a low DE of about 2. As is known, maltodextrose with a low DE, such as of about 2, gives rise to a high viscosity. Maltodextrose with a high DE, such as of about 47 gives rise to a low viscosity, but is very sweet. The combination of both maltodextroses optimizes the balance between sweetness and viscosity. In one embodiment of the present invention, the carbohydrate includes at least 65 weight%, preferably at least 90 weight%, based on total weight of carbohydrate of maltodextrose with a DE > 40, preferably with a DE of about 47 and 0 to 10 weight% of maltodextrose with a DE 2 to 10, preferably with a DE of about 2. In another embodiment of the present invention, the carbohydrate includes trehalose. As was indicated, it is one of the main objects of the invention to provide a nutritional composition with a low viscosity. Sucrose is very well suited for such purpose, but gives rise to very sweet compositions, which are in general disliked by the consumer. Maltodextrose with a low DE, such as of about 2, does not suffer from the latter drawback, but gives rise to a high viscosity. Maltodextrose with a high DE, such as of about 47 gives rise to a low viscosity, but is again very sweet, and gives further rise to the undesired Maillard reactions. Trehalose is a preferred choice of carbohydrate, as it gives rise to a low viscosity, no undesired Maillard reactions and it has a sweetness about half of that of sucrose. In one embodiment of the present invention, the carbohydrate includes trehalose in an amount of 20 % to 60 % of the weight of the carbohydrate, in an amount of 20 % to 45 %, more preferably in an amount of 25 % to 45 % of the weight of the carbohydrate.
Vitamins and minerals
The composition according to the invention may contain a variety of vitamins and minerals. Overall, the composition according to the invention preferably includes at least 100 % of the United States Recommended Daily Allowance (USRDA) of vitamins and minerals in a one litre portion.
In one embodiment of the present invention, the composition according to the invention provides all necessary vitamins and minerals. For example, the composition according to the invention preferably provides 6 mg of zinc per 100 ml of the composition which is beneficial for tissue repair in a healing patient. Preferably, the composition according to the invention (also) provides 25 mg of vitamin C per 100 ml of the composition to aid patients with more severe healing requirements. Further, preferably, the composition according to the invention (also) provides 2.25 mg iron per 100 ml of the composition. Iron is beneficial in maintaining bodily fluids as well as circulatory system functions in an elderly patient.
In another embodiment of the present invention, the amount of divalent ions ranges between 170 mg/100 ml and 300 mg/100 ml and preferably between 180 mg/100 ml and 280 mg/100 ml. Preferably, the amount of calcium ranges between 155 mg/100 ml and 300 mg/100 ml and preferably between 190 mg/100 ml and 250 mg/100 ml. The phosphorus content can be above
10 mg per g of protein, with a calcium to phosphorus weight ratio between 1.0 and 2.0, preferably between 1.1 and 1.7. Carnitin may advantageously be present in an amount of 8 mg/100 ml to 1000 mg/100 ml, preferably 10 mg/100 ml to 100 mg/100 ml of composition; it may have the form of carnitin, alkyl carnitin, acyl carnation or mixtures thereof. Organic acids are preferably present at a level of between 0.1 g/100 ml to 6 g/100 ml, especially 0.25 g/100 ml to 3 g/100 ml. These acids include short fatty acids such as acetic acid, hydroxy acids such as lactic acid, gluconic acid, and preferably polyvalent hydroxy acids, such as malic acid and citric acid. In one embodiment of the present invention, the present composition also comprises citric acid.
Prebiotics
The liquid enteral nutritional composition according to the invention may be fortified with a prebiotic, for example, with non-digestible carbohydrates (dietary fibres), such as fructo- oligosaccharides and/or inulin. In an embodiment, the composition according to the invention comprises 0.5 g/100 ml to 6 g/100 ml of non-digestible carbohydrates. Herein non-digestible carbohydrates are also referred to as dietary fibres. The dietary fibres include non-digestible oligosaccharides having a DP of 2 to 20, preferably 2 to 10. More preferably, these oligosaccharides do not contain substantial amounts (less than 5 weight%) of saccharides outside these DP ranges, and they are soluble. These oligosaccharides may comprise fructo- oligosaccharides (FOS), trans-galacto-oligosaccharides (TOS), xylo-oligosaccharides (XOS), soy oligosaccharides, and the like. Optionally, also higher molecular weight compounds such
as inulin, cellulose, resistant starch and the like may be incorporated in the composition according to the invention. The amount of insoluble dietary fibre such as cellulose is preferably lower than 20 weight% of the dietary fibre fraction of the composition according to the invention, and/or below 0.4 g/100 ml. The amount of thickening polysaccharides such as carrageenans, xanthans, pectins, galactomannans and other high molecular weight (DP > 50) indigestible polysaccharides is preferably low, i.e. less than 20 % of the weight of the dietary fibre fraction, or less than 1 g/100 ml. Instead, hydrolysed polysaccharides such as hydrolysed pectins and galactomannans can advantageously be included.
A preferred dietary fibre component is an indigestible oligosaccharide with a chain length (DP) of 2 to 10, for example Fibersol® (resistant oligoglucose), in particular hydrogenated
Fibersol®, or a mixture of oligosaccharides having a DP of 2 to 10, such as fructo- oligosaccharides or galacto-oligosaccharides, which may also contain a small amount of higher saccharides (e.g. with a DP of 11 to 20). Such oligosaccharides preferably comprise 50 weight% to 90 weight% of the fibre fraction, or 0.5 g/100 ml to 3 g/100 ml of the composition according to the invention. Other suitable fibre components include saccharides that have only partial digestibility.
Viscosity
In one embodiment of the present invention, the viscosity of the liquid enteral nutritional composition is lower than 500 mPa.s , measured at 20 0C (i.e. room temperature) at a shear rate of 100 s"1, preferably between 10 and 200 mPa.s , more preferably between 10 and 100 mPa.s, most preferably below 50 mPa.s. The viscosity may suitably be determined using a rotational viscosity meter using a cone/plate geometry. This viscosity is ideal for orally administering the liquid enteral nutritional composition according to the invention because a person may easily consume a serving having a low viscosity such as that displayed by the present invention. This viscosity is also ideal for unit dosages that are tube fed.
In one embodiment of the present invention, the density of the composition ranges between 1.00 g/ml and 1.20 g/ml, especially between 1.10 g/ml and 1.18 g/ml.
Dosage unit
The liquid enteral nutritional composition according to the invention may have the form of a complete food, i.e. it can meet all nutritional needs of the user. As such, it preferably contains
1200 to 2500 kcal per daily dosage. The daily dosage amounts are given with respect to a daily energy supply of 2000 kcal to a healthy adult having a body weight of 70 kg. For persons of different condition and different body weight, the levels should be adapted accordingly. It is understood that the average daily energy intake preferably is about 2000 kcal. The complete food can be in the form of multiple dosage units, e.g. from 4 (250 ml/unit) to 20 units (50 ml/unit) per day for an energy supply of 2000 kcal/day using a liquid enteral nutritional composition according to the invention of 2.0 kcal/ml.
The liquid enteral nutritional composition can also be a food supplement, for example to be used in addition to a non-medical food. Preferably as a supplement, the liquid enteral nutritional composition contains per daily dosage less than 1500 kcal, in particular as a supplement, the liquid enteral nutritional composition contains 400 to 1000 kcal per daily dose. The food supplement can be in the form of multiple dosage units, e.g. from 2 (250 ml/unit) to 10 units (50 ml/unit) per day for an energy supply of 1000 kcal/day using a liquid enteral nutritional composition according to the invention.
In one embodiment of the present invention, a unit dosage comprises any amount of the liquid enteral nutritional composition according to the invention between 10 ml and 250 ml, the end values of this range included, preferably any amount between 25 ml and 200 ml, the end values of this range included, more preferably any amount between 50 ml and 150 ml, the end values of this range included, most preferably about 125 ml. For example, a person receiving 50 ml unit dosages can be given 10 unit dosages per day to provide nutritional support using a liquid enteral nutritional composition according to the invention of 2.0 kcal/ml. Alternatively a person receiving 125 ml unit dosages can be given 4 or 5 or 6 or 7 or 8 unit dosages per day to provide nutritional support using a liquid enteral nutritional composition according to the invention. Such small dosage units are preferred because of better compliance.
In one embodiment of the present invention, the composition is provided in a ready to use liquid form and does not require reconstitution or mixing prior to use. The composition according to the invention can be tube fed or administered orally. For example, the composition according to the invention can be provided in a can, on spike, and hang bag.
However, a composition may be provided to a person in need thereof in powder form, suitable for reconstitution using an aqueous solution or water such that the composition according to the invention is produced. Thus in one embodiment of the present invention, the present composition is in the form of a powder, accompanied with instructions to dissolve or reconstitute in an aqueous composition or water to arrive at the liquid nutritional enteral composition according to the present invention. In one embodiment of the present invention, the present liquid nutritional enteral composition may thus be obtained by dissolving or reconstituting a powder, preferably in an aqueous composition, in particular water.
In one embodiment of the present invention, the composition according to the invention is packaged. The packaging may have any suitable form, for example a block-shaped carton, e.g. to be emptied with a straw ; a carton or plastic beaker with removable cover ; a small- sized bottle for example for the 80 ml to 200 ml range, and small cups for example for the 10 ml to 30 ml range. Another suitable packaging mode is inclusion of small volumes of liquid (e.g. 10 ml to 20 ml) in edible solid or semi-solid hulls or capsules, for example gelatine-like coverings and the like. Another suitable packaging mode is a powder in a container, e.g. a sachet, preferably with instructions to dissolve or reconstitute in an aqueous composition or water.
Preparation The liquid enteral nutritional composition according to the invention may be prepared by the method as outlined in Figure 1. Basically, the whey protein, carbohydrates and minerals are dispersed into water and the pH is adjusted using a suitable acid, such as lactic acid, citric acid, phosphoric acid and the like. The fat is blended into the product and this pre-emulsion is homogenized. This aqueous emulsion is subsequently atomized using the method of the invention, flash-cooled and collected. Optionally, the final pH and dry matter of the emulsion may be adjusted. The resulting product is subsequently pasteurized or sterilized using the known methods, such as, UHT processes and filled into containers or pasteurized or sterilized in containers in a retort. The liquid enteral nutritional composition according to the invention may alternatively be prepared by the method as outlined in Figure 7. Basically, the whey protein, carbohydrates and minerals are dispersed into water and the pH is adjusted using a suitable acid or base. The fat is blended into the product and this pre-emulsion is homogenized. This aqueous emulsion is subsequently atomized, flash-cooled and collected in an aseptic tank from which it can be filled into aseptic containers.
Effectivity
The present invention also concerns a method of providing nutrition to a person in need thereof, comprising the steps of administering to said person the nutritional composition according to the present invention. Said person may be an elderly person, a person that is in a disease state, a person that is recovering from a disease state, or a person that is malnourished. Said person may also be a healthy person, such as a sportsman or active elderly.
In a further aspect, the present invention relates to the non-hydrolysed heat-treated globular protein per se obtainable by the process according to the invention, and any product, formulation or composition comprising said heat-treated globular proteins, in particular whey proteins, in any form, such as a solution, suspension, dispersion, nutritional composition, medicament, or powder, in any concentration conceivable.
The invention will now be further elucidated by several examples, without being limited thereby.
FIGURES
Figure 1: Flow chart of a process for the manufacture of an acidic protein formula (12 g/100 ml) based on non-hydrolysed whey protein, according to the invention (Example 1 and Example 2). Figure 2: Particle size distribution of the formulation of Example 1, processed according to the flow chart of Figure 1, as measured with a Malvern Mastersizer 2000.
(a): product after homogenization at 30 0C and a pressure of 550/50 bar;
(b): product after spray-cooking at 110 0C for approximately 50 ms;
(c): product after UHT-pasteurization at 92°C for 30 sec using a plate heat exchanger. The product is liquid with a viscosity of 150 mPa.s at a shear rate of
100 s"1; the product has a smooth mouth feel.
Figure 3: Particle size distribution of the formulation of Example 1 , processed with a Scraped Surface Heat Exchanger (SSHE), as measured with a Malvern Mastersizer 2000. (a): particle size distribution before SSHE processing,
(b): particle size distribution after SSHE processing.
Figure 4: Flow chart of a process for the manufacture of an acidic protein formula (16 g/100 ml) based on non-hydrolysed whey protein, according to the invention (Example 3).
Figure 5: Particle size distribution of the formulation of Example 3, processed according to the flow chart of Figure 4, as measured with a Malvern Mastersizer 2000.
(a): product after homogenization at 30 0C and a pressure of 550/50 bar but before spray-cooking;
(b): product after spray-cooking at 120 0C for approximately 50 ms;
(c): product after UHT-pasteurization at 92°C for 30 sec using a plate heat exchanger.
(d): product after retort -pasteurization at 92°C for 30 sec. Figure 6: Viscosity of spray-cooked and non spray-cooked samples of Example 3 when subjected to a temperature/time profile where:
Curve a) is the temperature/time profile; Curve b) is the viscosity versus time for a non spray-cooked sample;
Curve c) is the viscosity versus time for a spray-cooked sample.
The left Y-axis refers to the viscosity, the right Y-axis to the temperature. Time is plotted on the x-axis.
Figure 7: Flow chart of a process for the manufacture of a neutral protein formula (16 g/100 ml) based on whey protein (Example 4).
EXAMPLES
A number of compositions were manufactured using the method according to the invention. These are summarized in Table 1.
Table 1
Example 1: Acidic whey protein composition (12 g/100 ml) (composition Al)
A flow chart of the process is shown in Figure 1. The protein ( WPC powder of Lactalis, Prolacta 80), carbohydrates and minerals were dispersed in water and the solution was set to pH 4.0 using 50 % lactic acid. The oil was blended into the product and the pre-emulsion was homogenised at 400C in a 2-stage homogenizer at a pressure of 550/50 bar. The product was then atomised into the spray-cooking chamber and instantly heated to 1100C by mixing with steam and held at this temperature for approximately 50 msec. Subsequently, the product was flash-cooled to 500C and pumped into a holding tank. The final pH of the product was adjusted to pH 4.0 and the product was then UHT pasteurised at 92°C for 30 sec and filled into 200 ml bottles. The product was liquid, with a viscosity of 150 mPa.s at 20°C at a shear rate of 100 s"1. The product had a smooth mouth feel. This is confirmed by the particle size distribution (Figure 2), which shows that the spray-cooking has little effect on the particle
size. Moreover, the spray-cooking step appears to have stabilised the protein aggregates against further aggregation: the particle size after UHT pasteurisation is nearly unchanged compared to the spray cooked intermediate product. The average particle diameter as obtained from static light scattering (Malvern Mastersizer 2000), d[4,3], after homogenisation ( a), spray-cooking (b) and UHT pasteurisation (c) were 7.7μm, 6.0μm and 5.4μm, respectively.
Example 2: Acidic whey protein composition (12 g/100 ml) (composition A2)
A recipe with composition A2 was made according to the process of Example 1. WPI powder from Fonterra (LGI 895) was used as the protein source. The final product was liquid, with a very low viscosity of 15 mPa.s at a shear rate of 100 s"1. The product had a smooth mouth feel. The average particle diameter as obtained from static light scattering (Malvern Mastersizer 2000), d[4,3], after UHT pasteurisation was 5.7 μm. Composition A5 was made in a similar way as composition A2.
Example 3: Acidic whey protein composition (16 g/100 ml) (composition A3)
A flow chart of the process is shown in Figure 4. The protein (WPI) (Bipro®, Davisco), carbohydrates and minerals were dispersed in water and the solution was set to pH 4.1 using citric acid. The oil was blended into the product and the pre-emulsion was homogenised at 400C in a 2-stage homogenizer at a pressure of 550/50 bar. The product was then atomised into the spray-cooking chamber and instantly heated to 1200C by mixing with steam and held at this temperature for approximately 50 msec. Subsequently, the product was flash-cooled to 500C and pumped into a holding tank. The final pH of the product was adjusted to pH 4.1 and the product was split in two batches. One batch was then UHT pasteurised at 92°C for 30 sec and filled aseptically into aseptic 200 ml bottles. The product was liquid, with a viscosity of 75 mPa.s at a shear rate of 100 s"1. The other batch was retorted (15 minutes at 92°C). This product was liquid with a viscosity of 162 mPa.s at a shear rate of 100 s"1 Both products had a smooth mouth feel. This is confirmed by the particle size distribution (Figure 5), which shows that the spray-cooking has little effect on the particle size. Moreover, the spray-cooking step appears to have stabilised the protein aggregates against further aggregation: the particle size after UHT and retort pasteurisation is nearly unchanged compared to the spray-cooked intermediate product. The average particle diameter as obtained from static light scattering (Malvern Mastersizer 2000), d[4,3], after homogenisation (a), spray-cooking (b) and UHT
pasteurisation (c) or retorting (d) were 4.7 μm, 3.7 μm, 3.9 μm or 3.8, respectively. It was observed that the mineral levels had only small effects on the final product characteristics like particle size, viscosity and shelf life stability.
In order to illustrate the effect of protein stabilization during spray-cooking, non spray-cooked and spray-cooked emulsions were subjected to the same heat treatment in a rheometer. Samples were heated up to 90°C, kept at 90° for 10 minutes and cooled back while measuring the viscosity. The temperature versus time curve is given in Figure 6, curve (a). As can be seen, the non spray-cooked emulsion (b) shows a large jump in viscosity when the temperature exceeds 80°C, while the viscosity of the spray-cooked emulsion (c) largely stays unaffected, illustrating the stabilizing effect of the method according to the invention.
Example 4: Neutral whey protein composition (16 g/100 ml) (composition A4)
A flow chart of the process is shown in Figure 7. The whey protein isolate (WPI) (Bipro®, Davisco) and sucrose were dispersed in demineralised water and the solution was adjusted to pH 7.5 using a 10% KOH solution. Oil was blended into the product and the pre-emulsion was homogenised at 40 0C in a 2-stage homogenizer at a pressure of 550/50 bar. The product was then atomised into the spray-cooking chamber and instantly heated to 1700C by mixing with steam and held at this temperature for approximately 100 ms. Subsequently, the product was flash-cooled to 55°C and aseptically filled into aseptic 200 ml bottles. The product was liquid, with a viscosity of 97 mPa.s at a shear rate of 100 s"1. The product had a smooth mouth feel. This is confirmed by the particle size distribution which shows that the spray-cooking has little effect on the particle size. If anything, the particles become smaller during the process. The average particle diameter as obtained from static light scattering (Malvern Mastersizer 2000), d[4,3], after homogenisation (a), spray-cooking (b) were 0.48 μm and 0.29 μm, respectively.
Example 5: Comparative examples
The method according to the invention is compared with several other methods commonly employed in the field of nutritional compositions using the ingredients of composition Al. A summary is given in Table 2. Yoghurt like products with a pH less than pH 4.2 require a
pasteurization step (either 900C, 15 min or 92°C, 30 sec) for long shelf life products. The temperature required for pasteurization is well above the denaturation temperature of whey proteins. Denatured whey proteins are reactive molecules capable of aggregate formation. In the experiments we have observed that the same formulation can form a gel or a liquid product depending on the heating conditions. For example, slow heating in a rheometer, tube heat exchanger, or during gentle mixing in the retort results in a gelled product. However, when the product is heated under high shear in the surface scraped heat exchanger or heated instantaneously to above the denaturation temperature (as in the spray-cooking technique), a liquid products result. From Table 2, it can be observed that in the case of products that are retort -pasteurized or pasteurized in a tube or plate heat exchanger at a temperature of 800C for 30 seconds, large protein aggregates form, leading to gel formation and clogging of the processing equipment. It was not possible to process the composition Al, A2 or A3 using this technique. We also attempted to process composition Al using a surface scraped heat exchanger (SSHE). This technique resulted in a liquid formulation; however the product had an extremely sandy mouth feel, likely due to the formation of large aggregates. This is confirmed by comparing the particle size distribution of the product (Figure 3 ). The average particle size, d[4,3], increases from 7.7 μm (a) to 38 μm (b) as a result of the SSHE processing. However, it is interesting to note that the aggregates did not agglomerate to form a gel, suggesting that high shear enabled the formation of inert, but aggregated proteins having a large and undesirable size.
Table 2
Rating : — : bad ; 0 : moderate ; + : good ; ++ : very good
It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications may be made without departing from the spirit and scope of the invention and without diminishing its advantages. It is therefore intended that such changes and modifications are covered by the appended claims.
Claims
I. Liquid enteral nutritional composition comprising 9 to 20 g non-hydrolysed globular proteins per 100 ml of the composition.
2. Liquid enteral nutritional composition according to claim 1, wherein the globular protein is selected from the group consisting of whey protein, pea protein, soy protein, and any mixture thereof.
3. Liquid enteral nutritional composition according to claim 2, wherein the whey protein is selected from the group consisting of β-lactoglobulin, α-lactalbumin, serum albumin, or any mixture thereof.
4. Liquid enteral nutritional composition according to claim 3, wherein the whey protein source is whey protein concentrate (WPC), whey protein isolate (WPI), or any mixture thereof.
5. Liquid enteral nutritional composition according to any one of claims 1 to 4, wherein the pH is about 2 to 8, preferably about 4 to 7.
6. Liquid enteral nutritional composition according to any one of claims 1 to 5, wherein the composition has an energy density of at least 1.5 kcal/ml.
7. Liquid enteral nutritional composition according to any one of claims 1 to 6, wherein the amount of non-hydrolysed globular proteins is at least 85 weight% of the total protein.
8. Liquid enteral nutritional composition according to any one of claims 1 to 7, further comprising a non-globular protein.
9. Liquid enteral nutritional composition according to claim 8, wherein the non-globular protein is selected from the group of casein, caseinate, micellar casein isolate, and any mixture thereof.
10. Liquid enteral nutritional composition according to any one of claims 1 to 9, further comprising fat, said fat providing between 20 to 40 % of the total energy content of the composition.
I I. Liquid enteral nutritional composition according to any one of claims 1 to 10, wherein the fat comprises long chain triglycerides.
12. Liquid enteral nutritional composition according to any one of claims 1 to 11, further comprising carbohydrate, said carbohydrate providing between 30 to 60 % of the total energy content of the composition.
13. Liquid enteral nutritional composition according to claim 12, wherein the carbohydrate includes maltodextrose with a DE of > 30, preferably with a DE of about 47.
14. Liquid enteral nutritional composition according to claim 12, wherein the carbohydrate includes maltodextrose with a DE of 2 to 10, preferably with a DE of about 2.
15. Liquid enteral nutritional composition according to claim 12, wherein the carbohydrate includes trehalose.
16. Liquid enteral nutritional composition according to any one of claims 1 to 15, wherein the viscosity of the composition is lower than 500 mPa.s, measured at 200C at a shear rate of 100 s"1.
17. Liquid enteral nutritional composition according to any one of claims 1 to 16, in a unit dosage of about 125 ml.
18. Liquid enteral nutritional composition comprising : a) about 12 g of non-hydro lysed whey per 100 ml of the composition, said protein providing about 30 % of the total energy content of the composition; b) fat providing about 25 % of the total energy content of the composition; c) carbohydrate providing about 45 % of the total energy content of the composition, said composition having an energy density of about 1.6 kcal/ml.
19. Liquid enteral nutritional composition comprising : a) about 16 g of non-hydro lysed whey per 100 ml of the composition, said protein providing about 27 % of the total energy content of the composition; b) fat providing about 31 % of the total energy content of the composition; c) carbohydrate providing about 42 % of the total energy content of the composition, said composition having an energy density of about 2.4 kcal/ml.
20. A method of providing nutrition to a person in need thereof, comprising the steps of administering to said person the nutritional composition according to any one of claims 1 to 19.
21. The method according to claim 20, wherein the person is an elderly person, a person that is in a disease state, a person that is recovering from a disease state, a person that is malnourished, a sportsman, or an active elderly.
22. Method for the heat-treatment of non- hydro lysed globular proteins, comprising the 5 consecutive steps of: a) adjusting the pH of an aqueous composition comprising non-hydrolysed globular proteins to a value of between about 2 and 8; b) converting the composition of non-hydrolysed globular proteins obtained in step a) into an aerosol; 0 c) subjecting the aerosol obtained in step b) to a temperature of 100 to 190 0C during a time of about 10 to 300 milliseconds; d) flash-cooling the heat-treated aerosol obtained in step c) to a temperature below 85°C to obtain an aqueous solution comprising heat-treated globular proteins.
23. Method according to claim 22, wherein at least 85 weight% of the non-hydrolysed5 globular proteins is whey protein.
24. Heat-treated globular proteins, obtainable by the method according to claim 22 or 23.
25. Product comprising heat-treated globular proteins according to claim 24.
26. Product according to claim 25, wherein said product is a solution, suspension, dispersion, nutritional composition, medicament or powder. Q * * * * * *
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/NL2008/050141 WO2009113845A1 (en) | 2008-03-12 | 2008-03-12 | High protein liquid enteral nutritional composition |
US12/746,135 US20110021421A1 (en) | 2007-12-05 | 2008-12-05 | Liquid enteral nutritional composition with a low specific protein volume |
BRPI0820951-0A2A BRPI0820951A2 (en) | 2007-12-05 | 2008-12-05 | NET ENTERAL NUTRITIONAL COMPOSITION AND METHOD FOR PROVIDING NUTRITION TO A PERSON IN NEED OF THE SAME |
MX2010006195A MX2010006195A (en) | 2007-12-05 | 2008-12-05 | Liquid enteral nutritional composition with a low specific protein volume. |
PCT/NL2008/050776 WO2009072884A1 (en) | 2007-12-05 | 2008-12-05 | Liquid enteral nutritional composition with a low specific protein volume |
CN2008801249546A CN101909468A (en) | 2007-12-05 | 2008-12-05 | Liquid enteral nutritional composition with a low specific protein volume |
RU2010127252/13A RU2471370C2 (en) | 2007-12-05 | 2008-12-05 | Liquid enteral nutritional composition with low specific volume of protein |
EP08858245A EP2230941A1 (en) | 2007-12-05 | 2008-12-05 | Liquid enteral nutritional composition with a low specific protein volume |
PL14185561.9T PL2835059T3 (en) | 2008-03-12 | 2009-03-12 | High protein liquid enteral nutritional composition |
ES09718670T ES2414534T3 (en) | 2008-03-12 | 2009-03-12 | High protein liquid enteral nutritional composition |
EP13159400.4A EP2612561B1 (en) | 2008-03-12 | 2009-03-12 | High protein liquid enteral nutritional composition |
EP14185561.9A EP2835059B1 (en) | 2008-03-12 | 2009-03-12 | High protein liquid enteral nutritional composition |
PL13159400T PL2612561T3 (en) | 2008-03-12 | 2009-03-12 | High protein liquid enteral nutritional composition |
DK14185561.9T DK2835059T3 (en) | 2008-03-12 | 2009-03-12 | Liquid enteral nutritional composition with high protein content |
EP09718670.4A EP2252167B1 (en) | 2008-03-12 | 2009-03-12 | High protein liquid enteral nutritional composition |
DK13159400.4T DK2612561T3 (en) | 2008-03-12 | 2009-03-12 | Liquid enteral nutritional composition with high protein content |
MX2010009989A MX2010009989A (en) | 2008-03-12 | 2009-03-12 | High protein liquid enteral nutritional composition. |
US12/921,694 US8815797B2 (en) | 2008-03-12 | 2009-03-12 | High protein liquid enteral nutritional composition |
PL09718670T PL2252167T3 (en) | 2008-03-12 | 2009-03-12 | High protein liquid enteral nutritional composition |
RU2010141720/13A RU2489905C2 (en) | 2008-03-12 | 2009-03-12 | Liquid enteral nutritional composition with high protein content |
DK09718670.4T DK2252167T3 (en) | 2008-03-12 | 2009-03-12 | High protein liquid enteral nutritional composition |
CN200980107525.2A CN102083329B (en) | 2008-03-12 | 2009-03-12 | High protein liquid enteral nutritional composition |
BRPI0909206-4A BRPI0909206B1 (en) | 2008-03-12 | 2009-03-12 | NUTRITIONAL NET COMPOSITION PACKED, AND METHOD FOR PREPARING AN ENTERAL NUTRITIONAL NET COMPOSITION " |
PCT/NL2009/050120 WO2009113858A1 (en) | 2008-03-12 | 2009-03-12 | High protein liquid enteral nutritional composition |
US14/337,085 US9420816B2 (en) | 2008-03-12 | 2014-07-21 | High protein liquid enteral nutritional composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/NL2008/050141 WO2009113845A1 (en) | 2008-03-12 | 2008-03-12 | High protein liquid enteral nutritional composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009113845A1 true WO2009113845A1 (en) | 2009-09-17 |
Family
ID=39744804
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2008/050141 WO2009113845A1 (en) | 2007-12-05 | 2008-03-12 | High protein liquid enteral nutritional composition |
PCT/NL2009/050120 WO2009113858A1 (en) | 2008-03-12 | 2009-03-12 | High protein liquid enteral nutritional composition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2009/050120 WO2009113858A1 (en) | 2008-03-12 | 2009-03-12 | High protein liquid enteral nutritional composition |
Country Status (10)
Country | Link |
---|---|
US (2) | US8815797B2 (en) |
EP (3) | EP2252167B1 (en) |
CN (1) | CN102083329B (en) |
BR (1) | BRPI0909206B1 (en) |
DK (3) | DK2612561T3 (en) |
ES (1) | ES2414534T3 (en) |
MX (1) | MX2010009989A (en) |
PL (3) | PL2835059T3 (en) |
RU (1) | RU2489905C2 (en) |
WO (2) | WO2009113845A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010043415A3 (en) * | 2008-10-17 | 2010-11-25 | Nestec S.A. Ashby, Kevin | Whey protein compositions, methods and uses |
WO2012081982A2 (en) * | 2010-12-17 | 2012-06-21 | N.V. Nutricia | Whey protein composition with a reduced astringency |
US8409651B2 (en) | 2007-12-05 | 2013-04-02 | N. V. Nutricia | High energy liquid enteral nutritional composition |
KR20140106535A (en) * | 2011-11-02 | 2014-09-03 | 폰테라 코-오퍼레이티브 그룹 리미티드 | Dairy product and process |
CN104284597A (en) * | 2012-03-12 | 2015-01-14 | N·V·努特里奇亚 | Process for the humanization of animal skim milk and products obtained thereby |
EP2555634B1 (en) | 2010-04-09 | 2016-03-09 | Roquette Freres | Process for manufacturing soluble and functional plant proteins, products obtained and uses |
FR3027806A1 (en) * | 2014-11-03 | 2016-05-06 | Even Sante Ind | ENTERAL NUTRITION COMPOSITION |
EP2911524B1 (en) | 2012-10-29 | 2016-07-27 | Roquette Frères | Method for producing protein compositions of low solubility, compositions produced, and use thereof in bread-making products |
US9420816B2 (en) | 2008-03-12 | 2016-08-23 | N.V. Nutricia | High protein liquid enteral nutritional composition |
WO2017102258A1 (en) * | 2015-12-18 | 2017-06-22 | Nestec S.A. | Heat sterilized high protein compositions with hydrolyzed protein from a continuous process with at least one endopeptidase |
EP2680711B1 (en) | 2011-03-01 | 2018-02-21 | Nestec S.A. | Extensional viscosity to promote safe swallowing of food boluses |
EP3298907B1 (en) | 2016-09-23 | 2019-04-24 | Fresenius Kabi Deutschland GmbH | High calorie, uht treated liquid nutritional compositions |
US10674739B2 (en) | 2013-09-19 | 2020-06-09 | N.V. Nutricia | Method for processing animal skim milk |
CN111869883A (en) * | 2020-07-30 | 2020-11-03 | 北京壹诺药业有限公司 | Multi-protein formula composition and preparation method and application thereof |
WO2021048204A1 (en) * | 2019-09-13 | 2021-03-18 | Groupe Lactalis | Long-life liquid nutritional composition with high soluble milk protein content |
CN112752516A (en) * | 2018-06-27 | 2021-05-04 | 阿尔拉食品公司 | Acidic beta-lactoglobulin beverage product |
JP2021534730A (en) * | 2018-06-27 | 2021-12-16 | アーラ フーズ エイエムビーエイ | Acidic β-lactoglobulin beverage preparation |
EP3236784B1 (en) | 2014-12-26 | 2022-01-12 | Compagnie Gervais Danone | Composition comprising a mixture of proteins |
WO2023220339A1 (en) * | 2022-05-13 | 2023-11-16 | The Coca-Cola Company | Non-animal protein blends and compositions containing same |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005096845A1 (en) * | 2004-04-09 | 2005-10-20 | N.V. Nutricia | Liquid concentrated formula |
EP2298090B1 (en) | 2009-08-26 | 2016-01-13 | Jeffrey M. Golini | Pharmaceutical or nutraceutical composition |
WO2011078654A1 (en) | 2009-12-24 | 2011-06-30 | N.V. Nutricia | Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis |
EP2584920B1 (en) | 2010-06-28 | 2017-12-13 | Nestec S.A. | Hypocaloric, high protein nutritional compositions and methods of using same |
WO2012005568A1 (en) | 2010-07-07 | 2012-01-12 | N.V. Nutricia | Nutritional composition for the stimulation of muscle protein synthesis |
US20120015092A1 (en) | 2010-07-18 | 2012-01-19 | Grace Cahalane | High-Protein Beverages Comprising Whey Protein |
FR2978647B1 (en) | 2011-08-01 | 2013-08-16 | Groupe Lactalis | FUNCTIONAL AND STABLE PROTEIN MIXTURE FOR FOOD COMPOSITIONS INTENDED FOR PEOPLE REQUIRING IMPROVEMENT AND MAINTAINMENT OF THEIR PHYSICAL CONDITION. |
WO2013129912A1 (en) * | 2012-02-28 | 2013-09-06 | N.V. Nutricia | Energy-rich liquid nutritional composition having improved organoleptic properties |
JP6325439B2 (en) * | 2012-03-02 | 2018-05-16 | 株式会社明治 | Sterilization method |
FR2995763B1 (en) * | 2012-09-21 | 2016-09-02 | Roquette Freres | ASSEMBLING AT LEAST ONE PLANT PROTEIN AND AT LEAST ONE MILK PROTEIN |
MX2015007938A (en) * | 2012-12-18 | 2015-10-09 | Abbott Lab | Low viscosity, high caloric density oral nutritional composition and related methods. |
BR112015030767B1 (en) | 2013-06-10 | 2021-03-30 | N.V. Nutricia | USE OF A COMPOSITION |
US10045553B2 (en) | 2014-12-18 | 2018-08-14 | Mark H. Sterner | Legume/grain based food product with prebiotic/probiotic source |
CN106390528A (en) * | 2015-08-03 | 2017-02-15 | 安徽华明制药有限公司 | Vacuum bubble-removing apparatus used in preparation of enteral nutritional emulsion |
WO2017094669A1 (en) * | 2015-12-03 | 2017-06-08 | 株式会社明治 | Nutritional composition |
CA3013200A1 (en) | 2016-02-05 | 2017-08-10 | Abbott Laboratories | Whey protein based liquid nutritional composition |
EP3468390A1 (en) * | 2016-06-10 | 2019-04-17 | Nestec S.A. | Heat sterilized high protein enteral compositions with whey protein which comprises whey protein micelles and a source of casein |
WO2017211858A1 (en) * | 2016-06-10 | 2017-12-14 | Nestec S.A. | Heat sterilized high protein enteral compositions with whey protein which comprises whey protein micelles and a source of casein |
BR112019012944B1 (en) * | 2016-12-23 | 2023-03-21 | Arla Foods Amba | METHOD OF PREPARATION OF AN EDIBLE COMPOSITION |
US11197917B2 (en) | 2017-12-01 | 2021-12-14 | ByHeart, Inc. | Formulations for nutritional support in subjects in need thereof |
CN110558569B (en) * | 2018-06-05 | 2024-03-12 | 费森尤斯卡比德国有限公司 | Transparent liquid nutritional composition comprising acidic whey derived proteins |
EP3813536A1 (en) | 2018-06-27 | 2021-05-05 | Arla Foods amba | Novel method for preparing alpha-lactalbumin-enriched compositions, related products and uses e.g. in infant formulas |
WO2020007940A1 (en) * | 2018-07-03 | 2020-01-09 | Roquette Freres | Food composition comprising plant proteins and a potassium metaphosphate |
US20220000161A1 (en) * | 2018-11-20 | 2022-01-06 | Fonterra Co-Operative Group Limited | Dairy product and process |
CA3078001A1 (en) | 2019-04-11 | 2020-10-15 | Goli Nutrition Inc. | Apple cider vinegar nutritional supplement |
US20230051969A1 (en) | 2019-12-30 | 2023-02-16 | Arla Foods Amba | Method of producing dense whey protein nanogels, the resulting whey protein nanogels or nanogel compositions, and food products containing such whey protein nanogels or nanogel compositions |
CA3231264A1 (en) | 2021-10-14 | 2023-04-20 | Arla Foods Amba | Method of producing a modified whey protein composition by gentle oxidation, the modified whey protein composition, and nutritional uses of the modified whey protein composition |
CN115474690B (en) * | 2022-08-15 | 2023-11-10 | 华南理工大学 | Total nutrient special medical formula food emulsion taking plant integrins as unique protein sources and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030099761A1 (en) * | 2001-11-26 | 2003-05-29 | Rolf Jost | Shelf stable nutritional composition containing intact whey protein, process of manufacture and use |
US20040057867A1 (en) * | 2000-12-22 | 2004-03-25 | Nutricia N.V. | Pasteurizing or sterilizing |
EP1787528A1 (en) * | 2005-08-22 | 2007-05-23 | Kraft Foods Holdings, Inc. | Method of deflavoring whey protein using membrane electrodialysis |
WO2007108827A1 (en) * | 2006-03-23 | 2007-09-27 | Nestec S.A. | High-calorie nutritional supplement |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1277772A (en) | 1968-08-26 | 1972-06-14 | Kraftco Corp | Whey product |
US3843828A (en) * | 1970-06-01 | 1974-10-22 | Ralston Purina Co | Preparation of a simulated milk product |
US3764711A (en) * | 1971-03-29 | 1973-10-09 | Carnation Co | Acylated protein for coffee whitener formulations |
US4112123A (en) * | 1976-07-21 | 1978-09-05 | Beatrice Foods Co. | Nutritionally balanced single food composition and method of production |
US4280851A (en) | 1979-12-14 | 1981-07-28 | General Foods Corporation | Process for cooking or gelatinizing materials |
CA1201321A (en) | 1981-12-22 | 1986-03-04 | Anne-Marie Dahlen | Protein-fruit drink |
US4497836A (en) * | 1982-08-06 | 1985-02-05 | Dairy Technology Ltd. | Modified whey product and process including ultrafiltration and demineralization |
DK169248B1 (en) | 1987-09-02 | 1994-09-26 | Apv Pasilac As | Systems for continuous sterilization of liquids such as milk |
NO170313C (en) | 1987-12-02 | 1992-10-07 | Labatt Ltd John | PROCEDURE FOR THE PREPARATION OF A PROTEIN-CONTAINING, WATER DISSERTIBLE MACROCOLLOIDS |
US5149799A (en) | 1990-01-26 | 1992-09-22 | National Starch And Chemical Investment Holding Corporation | Method and apparatus for cooking and spray-drying starch |
ATE110531T1 (en) | 1990-11-01 | 1994-09-15 | Sandoz Nutrition Ltd | HIGH ACID SYSTEM CONTAINING FOOD FORMULATIONS. |
DK149591A (en) | 1991-08-22 | 1993-03-19 | Lube As | protein preparation |
DK180291D0 (en) | 1991-10-31 | 1991-10-31 | Apv Pasilac As | PROCEDURE FOR HEAT TREATMENT OF FRESH MILK |
US5780039A (en) * | 1992-04-23 | 1998-07-14 | Novartis Nutrition Ag | Orally-ingestible nutrition compositions having improved palatability |
US5256437A (en) * | 1992-06-19 | 1993-10-26 | Pall Corporation | Product and process of making sterile milk through dynamic microfiltration |
US5514655A (en) * | 1993-05-28 | 1996-05-07 | Abbott Laboratories | Enteral nutritional with protein system containing soy protein hydrolysate and intact protein |
ZA949789B (en) | 1993-12-30 | 1995-10-25 | Immunotec Res Corp Ltd | Process for making undenatured whey protein concentrate |
DE69518949T2 (en) | 1994-02-25 | 2001-02-01 | Societe Des Produits Nestle S.A., Vevey | Enteric composition containing micellar casein |
US5728678A (en) | 1995-06-06 | 1998-03-17 | Nestec Ltd. | Method and composition for providing nutrition to a renal failure patient |
US5641531A (en) * | 1995-09-28 | 1997-06-24 | Abbott Laboratories | Nutritional liquid supplement beverage and method of making same |
US6297273B1 (en) * | 1996-04-02 | 2001-10-02 | Mars, Inc. | Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions |
JP3132652B2 (en) | 1997-07-08 | 2001-02-05 | 明治乳業株式会社 | High energy gel nutrition composition |
JP2002530123A (en) | 1997-12-22 | 2002-09-17 | ニーロ、アクティーゼルスカブ | Method of applying ultra-short-time heat treatment to liquid |
US6475539B1 (en) | 1998-05-07 | 2002-11-05 | Abbott Laboratories | Nutritionally complete low pH enteral formula |
US6139900A (en) * | 1998-08-11 | 2000-10-31 | North Carolina State University | Method of forming whey protein products |
US5948452A (en) * | 1998-08-31 | 1999-09-07 | Monte; Woodrow C. | Process for producing low pH by-products from waste products of cheese production |
US6623781B2 (en) * | 1999-07-26 | 2003-09-23 | Cornell Research Foundation, Inc. | Microfiltration of skim milk for cheese making and whey proteins |
DE10006989A1 (en) | 2000-02-16 | 2001-08-23 | Nutricia Nv | Pharmaceutical or dietetic preparation for preventing cellular adhesion of pathogens, e.g. in treatment of infections, comprising carbohydrate having double bond-containing terminal uronic acid unit |
US6774111B1 (en) * | 2000-03-14 | 2004-08-10 | Abbott Laboratories | Carbohydrate system and a method for providing nutrition to a diabetic |
FR2808444B1 (en) | 2000-05-05 | 2004-03-26 | Francois Ballestra | USE OF A FRACTION OF EQUIDE MILK FOR THE MANUFACTURE OF A COMPOSITION HAVING AN INTERHIBITION ACTIVITY OF THE PRODUCTION OF INTERLEUKINE-1 AND COMPOSITION THUS OBTAINED |
US6592863B2 (en) | 2000-08-22 | 2003-07-15 | Nestec S.A. | Nutritional composition |
WO2002052166A1 (en) | 2000-12-26 | 2002-07-04 | Kayaba Industry Co., Ltd. | Outer shell unit and method of manufacturing the unit |
US6605310B2 (en) | 2001-06-06 | 2003-08-12 | Nestec S.A. | Calorically dense liquid oral supplement |
US20030099753A1 (en) | 2001-11-20 | 2003-05-29 | Yang Baokang | Juice based beverage compositions |
EP1314361B1 (en) | 2001-11-26 | 2007-08-08 | Nestec S.A. | "Shelf stable nutritional composition containing intact whey protein, process of manufacture and use" |
US20040258823A1 (en) | 2001-12-21 | 2004-12-23 | Therese Dufresne | Method of preparation of adapted foods |
AU2003231985A1 (en) | 2002-04-03 | 2003-10-20 | Solae, Llc | Process for producing a high solubility, low viscosity, isoflavone-enriched soy protein isolate and the products thereof |
AR042491A1 (en) | 2002-12-17 | 2005-06-22 | Nestec Sa | NUTRITIONAL FORMULA ACIDIFIED |
US20060062827A1 (en) | 2002-12-20 | 2006-03-23 | Gel Dynamics, Llc | Nutritional supplement composition and method |
CA2694872A1 (en) | 2003-01-31 | 2004-08-19 | Simply Thick Llc | Improved thickened beverages for dysphagia |
SG152271A1 (en) | 2003-10-24 | 2009-05-29 | Nutricia Nv | Immunemodulating oligosaccharides |
CA2548379C (en) * | 2003-12-12 | 2012-03-13 | Taiyo Kagaku Co., Ltd. | Compositions of galactomannan for the treatment of bowel diseases |
EP1563741A1 (en) | 2004-02-12 | 2005-08-17 | Campina Nederland Holding B.V. | Skimmed milk product for consumption and method for its preparation |
EP1725122A4 (en) | 2004-02-27 | 2009-08-19 | Byron Food Science Pty Ltd | Egg-like food product |
WO2005096845A1 (en) * | 2004-04-09 | 2005-10-20 | N.V. Nutricia | Liquid concentrated formula |
WO2005110112A1 (en) * | 2004-05-07 | 2005-11-24 | Wisconsin Alumni Research Foundation | Methods and compositions involving whey protein isolates |
MY153295A (en) | 2004-09-29 | 2015-01-29 | Nestec Sa | Nanoparticulated whey proteins |
US7906160B2 (en) * | 2004-10-07 | 2011-03-15 | Next Proteins, Inc. | Protein beverage and method of making the same |
US7897192B2 (en) * | 2004-10-07 | 2011-03-01 | Next Proteins, Inc. | High energy carbonated protein drink and method of making |
US7205018B2 (en) | 2004-10-07 | 2007-04-17 | Next Proteins, Inc. | Carbonated protein drink and method of making |
EP1654934A1 (en) | 2004-11-08 | 2006-05-10 | Ernst Neuenschwander | Method for preparing a denatured whey retentate, milk products containing such a whey retentate and apparatus for preparing such a whey retentate |
WO2006058083A2 (en) | 2004-11-24 | 2006-06-01 | Cornell Research Foundation, Inc. | Protein and calcium fortification system for clear and opaque beverages |
WO2006058538A1 (en) | 2004-11-30 | 2006-06-08 | Cp Kelco Aps | Method for producing a denatured protein material |
ES2307126T3 (en) | 2005-05-09 | 2008-11-16 | Compagnie Gervais Danone | PROCEDURE FOR THE PREPARATION OF PREPARATIONS BASED ON SOY AND MILK PROTEINS THAT PRESENT A TOTAL CONTENT OF ELEVATED PROTEINS. |
WO2007047592A1 (en) | 2005-10-17 | 2007-04-26 | Novozymes A/S | Process for producing cheese |
NO323912B1 (en) * | 2005-12-01 | 2007-07-16 | Tine Sa | Composition, method of preparation thereof, and use thereof. |
US20070190223A1 (en) | 2006-01-11 | 2007-08-16 | The Penn State Research Foundation | Soy/whey protein recovery composition |
ES2373400T3 (en) | 2006-03-27 | 2012-02-03 | Nestec S.A. | MILK PROTEIN MICELS. |
WO2007136263A1 (en) | 2006-05-22 | 2007-11-29 | Nizo Food Research B.V. | Protein encapsulated partocles |
IES20070714A2 (en) | 2006-10-06 | 2008-04-16 | Kerry Group Services Int Ltd | A milk protein composition and use thereof |
WO2008115046A1 (en) | 2007-03-22 | 2008-09-25 | N.V. Nutricia | Cereal-based infant nutrition with fibre |
JP5384333B2 (en) | 2007-04-27 | 2014-01-08 | 株式会社明治 | Liquid nutritional composition containing whey protein at high concentration and method for producing the same |
DK2178385T4 (en) | 2007-07-18 | 2022-01-31 | Campina Nederland Holding Bv | Heat-stable nutrient beverage and process for its preparation |
WO2009072869A1 (en) | 2007-12-05 | 2009-06-11 | N.V. Nutricia | High energy liquid enteral nutritional composition |
CN101909468A (en) | 2007-12-05 | 2010-12-08 | 荷兰纽迪希亚公司 | Liquid enteral nutritional composition with a low specific protein volume |
ES2640728T3 (en) | 2007-12-05 | 2017-11-06 | N.V. Nutricia | Liquid enteral nutritional composition based on protein-dense micellar casein |
WO2009113845A1 (en) * | 2008-03-12 | 2009-09-17 | N.V. Nutricia | High protein liquid enteral nutritional composition |
EP2230940B1 (en) | 2007-12-05 | 2014-08-20 | N.V. Nutricia | High energy liquid enteral nutritional composition |
US20090162494A1 (en) * | 2007-12-21 | 2009-06-25 | Chron-Si Lai | Method of Making Chilled Nutritional Emulsions |
IE20080476A1 (en) | 2008-06-10 | 2010-03-03 | Teagasc | Miscellar casein powders with different levels of calcium and cheeses prepared therefrom |
WO2012075570A1 (en) * | 2010-12-09 | 2012-06-14 | Mcgill University | Bioactive peptides and proteins containing bioactive peptides, their uses and processes for making the same |
-
2008
- 2008-03-12 WO PCT/NL2008/050141 patent/WO2009113845A1/en active Application Filing
-
2009
- 2009-03-12 RU RU2010141720/13A patent/RU2489905C2/en active
- 2009-03-12 EP EP09718670.4A patent/EP2252167B1/en not_active Revoked
- 2009-03-12 ES ES09718670T patent/ES2414534T3/en active Active
- 2009-03-12 US US12/921,694 patent/US8815797B2/en active Active
- 2009-03-12 DK DK13159400.4T patent/DK2612561T3/en active
- 2009-03-12 CN CN200980107525.2A patent/CN102083329B/en active Active
- 2009-03-12 DK DK14185561.9T patent/DK2835059T3/en active
- 2009-03-12 PL PL14185561.9T patent/PL2835059T3/en unknown
- 2009-03-12 MX MX2010009989A patent/MX2010009989A/en active IP Right Grant
- 2009-03-12 EP EP13159400.4A patent/EP2612561B1/en not_active Revoked
- 2009-03-12 BR BRPI0909206-4A patent/BRPI0909206B1/en active IP Right Grant
- 2009-03-12 EP EP14185561.9A patent/EP2835059B1/en active Active
- 2009-03-12 PL PL09718670T patent/PL2252167T3/en unknown
- 2009-03-12 PL PL13159400T patent/PL2612561T3/en unknown
- 2009-03-12 WO PCT/NL2009/050120 patent/WO2009113858A1/en active Application Filing
- 2009-03-12 DK DK09718670.4T patent/DK2252167T3/en active
-
2014
- 2014-07-21 US US14/337,085 patent/US9420816B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040057867A1 (en) * | 2000-12-22 | 2004-03-25 | Nutricia N.V. | Pasteurizing or sterilizing |
US20030099761A1 (en) * | 2001-11-26 | 2003-05-29 | Rolf Jost | Shelf stable nutritional composition containing intact whey protein, process of manufacture and use |
EP1787528A1 (en) * | 2005-08-22 | 2007-05-23 | Kraft Foods Holdings, Inc. | Method of deflavoring whey protein using membrane electrodialysis |
WO2007108827A1 (en) * | 2006-03-23 | 2007-09-27 | Nestec S.A. | High-calorie nutritional supplement |
Non-Patent Citations (1)
Title |
---|
MELO T.S., HANSEN A.P.: "Effect of Ultra-High-Temperature Steam Injection on Model systems of Alpha-lactalbumin and Beta-Lactoglobulin", JOURNAL OF DAIRY SCIENCES, vol. 61, 1978, pages 710 - 713, XP002496653 * |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8409651B2 (en) | 2007-12-05 | 2013-04-02 | N. V. Nutricia | High energy liquid enteral nutritional composition |
US9345256B2 (en) | 2007-12-05 | 2016-05-24 | N.V. Nutricia | High energy liquid enteral nutritional composition |
US8999423B2 (en) | 2007-12-05 | 2015-04-07 | N. V. Nutricia | High energy liquid enteral nutritional composition |
US9420816B2 (en) | 2008-03-12 | 2016-08-23 | N.V. Nutricia | High protein liquid enteral nutritional composition |
EP2409575A1 (en) * | 2008-10-17 | 2012-01-25 | Nestec S.A. | Whey protein compositions, methods and uses |
US11882845B2 (en) | 2008-10-17 | 2024-01-30 | Societe Des Produits Nestle S.A. | Whey protein compositions and methods |
EP4238420A3 (en) * | 2008-10-17 | 2023-11-01 | Société des Produits Nestlé S.A. | Whey protein compositions, methods and uses |
US11246321B2 (en) | 2008-10-17 | 2022-02-15 | Societe Des Produits Nestle S.A. | Whey protein compositions and methods |
WO2010043415A3 (en) * | 2008-10-17 | 2010-11-25 | Nestec S.A. Ashby, Kevin | Whey protein compositions, methods and uses |
EP2348873B1 (en) | 2008-10-17 | 2019-01-16 | Nestec S.A. | Method of producing whey protein compositions and composition obtainable thereby |
EP2555634B1 (en) | 2010-04-09 | 2016-03-09 | Roquette Freres | Process for manufacturing soluble and functional plant proteins, products obtained and uses |
EP2651249B1 (en) | 2010-12-17 | 2019-07-24 | N.V. Nutricia | Method for making whey protein composition with a reduced astringency |
US20140296162A1 (en) * | 2010-12-17 | 2014-10-02 | N.V. Nutricia | Whey Protein Composition with a Reduced Astringency |
US9049882B2 (en) * | 2010-12-17 | 2015-06-09 | N.V. Nutricia | Whey protein composition with a reduced astringency |
WO2012081982A2 (en) * | 2010-12-17 | 2012-06-21 | N.V. Nutricia | Whey protein composition with a reduced astringency |
WO2012081971A1 (en) * | 2010-12-17 | 2012-06-21 | N.V. Nutricia | Whey protein composition with a reduced astringency |
WO2012081982A3 (en) * | 2010-12-17 | 2013-05-30 | N.V. Nutricia | Whey protein composition with a reduced astringency |
CN103369975A (en) * | 2010-12-17 | 2013-10-23 | N.V.努特里西阿公司 | Whey protein composition with a reduced astringency |
US10583097B2 (en) | 2011-03-01 | 2020-03-10 | Societe Des Produits Nestle S.A. | Extensional viscosity to promote safe swallowing of food boluses |
US11883370B2 (en) | 2011-03-01 | 2024-01-30 | Societe Des Produits Nestle S.A. | Extensional viscosity to promote safe swallowing of food boluses |
EP2680711B1 (en) | 2011-03-01 | 2018-02-21 | Nestec S.A. | Extensional viscosity to promote safe swallowing of food boluses |
EP3388070B1 (en) | 2011-03-01 | 2019-12-18 | Société des Produits Nestlé S.A. | Extensional viscosity to promote safe swallowing of food boluses |
KR20140106535A (en) * | 2011-11-02 | 2014-09-03 | 폰테라 코-오퍼레이티브 그룹 리미티드 | Dairy product and process |
US9386791B2 (en) | 2011-11-02 | 2016-07-12 | Fonterra Co-Operative Group Limited | Dairy product and process |
KR102025448B1 (en) | 2011-11-02 | 2019-09-25 | 폰테라 코-오퍼레이티브 그룹 리미티드 | Dairy product and process |
EP2773222A4 (en) * | 2011-11-02 | 2015-09-02 | Fonterra Co Operative Group | Dairy product and process |
US10772339B2 (en) | 2012-03-12 | 2020-09-15 | N.V. Nutricia | Process for the humanization of animal skim milk and products obtained thereby |
CN104284597B (en) * | 2012-03-12 | 2018-05-01 | N·V·努特里奇亚 | The humanized method of animal skimmed milk and thus obtained product |
CN104284597A (en) * | 2012-03-12 | 2015-01-14 | N·V·努特里奇亚 | Process for the humanization of animal skim milk and products obtained thereby |
EP3718410A1 (en) * | 2012-03-12 | 2020-10-07 | N.V. Nutricia | Process for the humanization of animal skim milk and products obtained thereby |
EP2825058B1 (en) * | 2012-03-12 | 2020-02-12 | N.V. Nutricia | Process for the humanization of animal skim milk and products obtained thereby |
EP2911524B2 (en) † | 2012-10-29 | 2019-08-14 | Roquette Freres | Method for producing protein compositions of low solubility, compositions produced, and use thereof in bread-making products |
EP2911524B1 (en) | 2012-10-29 | 2016-07-27 | Roquette Frères | Method for producing protein compositions of low solubility, compositions produced, and use thereof in bread-making products |
US10674739B2 (en) | 2013-09-19 | 2020-06-09 | N.V. Nutricia | Method for processing animal skim milk |
WO2016071621A1 (en) * | 2014-11-03 | 2016-05-12 | Even Sante Industrie | Enteral nutrition composition |
FR3027806A1 (en) * | 2014-11-03 | 2016-05-06 | Even Sante Ind | ENTERAL NUTRITION COMPOSITION |
EP3236784B1 (en) | 2014-12-26 | 2022-01-12 | Compagnie Gervais Danone | Composition comprising a mixture of proteins |
WO2017102258A1 (en) * | 2015-12-18 | 2017-06-22 | Nestec S.A. | Heat sterilized high protein compositions with hydrolyzed protein from a continuous process with at least one endopeptidase |
US10820618B2 (en) | 2015-12-18 | 2020-11-03 | Societe Des Produits Nestle S.A. | Heat sterilized high protein compositions with hydrolyzed protein from a continuous process with at least one endopeptidase |
EP3298907B1 (en) | 2016-09-23 | 2019-04-24 | Fresenius Kabi Deutschland GmbH | High calorie, uht treated liquid nutritional compositions |
EP3298907B2 (en) † | 2016-09-23 | 2022-10-19 | Fresenius Kabi Deutschland GmbH | High calorie, uht treated liquid nutritional compositions |
CN112752516A (en) * | 2018-06-27 | 2021-05-04 | 阿尔拉食品公司 | Acidic beta-lactoglobulin beverage product |
JP2021529532A (en) * | 2018-06-27 | 2021-11-04 | アーラ フーズ エイエムビーエイ | Acid β-lactoglobulin beverage preparation |
JP2021534730A (en) * | 2018-06-27 | 2021-12-16 | アーラ フーズ エイエムビーエイ | Acidic β-lactoglobulin beverage preparation |
CN112752516B (en) * | 2018-06-27 | 2024-01-16 | 阿尔拉食品公司 | Acidic beta-lactoglobulin beverage products |
WO2021048204A1 (en) * | 2019-09-13 | 2021-03-18 | Groupe Lactalis | Long-life liquid nutritional composition with high soluble milk protein content |
FR3100691A1 (en) * | 2019-09-13 | 2021-03-19 | Groupe Lactalis | LONG STORAGE LIQUID NUTRITIONAL COMPOSITION WITH A HIGH CONTENT OF SOLUBLE MILK PROTEINS. |
CN111869883B (en) * | 2020-07-30 | 2023-01-06 | 北京诺葆营养科技有限公司 | Multi-protein formula composition and preparation method and application thereof |
CN111869883A (en) * | 2020-07-30 | 2020-11-03 | 北京壹诺药业有限公司 | Multi-protein formula composition and preparation method and application thereof |
WO2023220339A1 (en) * | 2022-05-13 | 2023-11-16 | The Coca-Cola Company | Non-animal protein blends and compositions containing same |
Also Published As
Publication number | Publication date |
---|---|
ES2414534T3 (en) | 2013-07-19 |
PL2612561T3 (en) | 2015-04-30 |
DK2612561T3 (en) | 2014-12-01 |
US9420816B2 (en) | 2016-08-23 |
EP2252167B1 (en) | 2013-04-10 |
DK2252167T3 (en) | 2013-06-17 |
US8815797B2 (en) | 2014-08-26 |
RU2010141720A (en) | 2012-04-20 |
RU2489905C2 (en) | 2013-08-20 |
EP2835059B1 (en) | 2023-12-06 |
MX2010009989A (en) | 2010-11-10 |
PL2252167T3 (en) | 2013-09-30 |
EP2252167A1 (en) | 2010-11-24 |
US20110046048A1 (en) | 2011-02-24 |
EP2612561A1 (en) | 2013-07-10 |
PL2835059T3 (en) | 2024-05-13 |
US20140364361A1 (en) | 2014-12-11 |
EP2612561B1 (en) | 2014-11-05 |
BRPI0909206B1 (en) | 2018-01-02 |
CN102083329B (en) | 2014-12-10 |
EP2835059A1 (en) | 2015-02-11 |
CN102083329A (en) | 2011-06-01 |
BRPI0909206A2 (en) | 2015-08-04 |
DK2835059T3 (en) | 2024-01-02 |
WO2009113858A1 (en) | 2009-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9420816B2 (en) | High protein liquid enteral nutritional composition | |
US9049882B2 (en) | Whey protein composition with a reduced astringency | |
DK2249666T3 (en) | Protein-rich liquid enteral nutritional composition on a casein basis | |
US10092625B2 (en) | Liquid enteral nutritional composition with a low monovalent metal ion content | |
US20110021421A1 (en) | Liquid enteral nutritional composition with a low specific protein volume | |
AU2005230802B2 (en) | Liquid concentrated formula |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08723892 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08723892 Country of ref document: EP Kind code of ref document: A1 |